[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 4726
1. Gao X, Chen H, Fung TT, Logroscino G, Schwarzschild MA, Hu FB, Ascherio A: Prospective study of dietary pattern and risk of Parkinson disease. Am J Clin Nutr; 2007 Nov;86(5):1486-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective study of dietary pattern and risk of Parkinson disease.
  • BACKGROUND: Several studies have shown associations between Parkinson Disease (PD) risk and individual foods and nutrients with inconsistent results.
  • The prudent dietary pattern, characterized by high intakes of fruit, vegetables, and fish, was inversely associated with PD risk, but the Western pattern was not.

  • Genetic Alliance. consumer health - Parkinson Disease.
  • MedlinePlus Health Information. consumer health - Parkinson's Disease.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Epidemiol. 1999 Dec;28(6):1102-9 [10661654.001]
  • [Cites] J Am Diet Assoc. 2006 Nov;106(11):1759-65 [17081826.001]
  • [Cites] Am J Clin Nutr. 2001 Jan;73(1):1-2 [11124739.001]
  • [Cites] Am J Clin Nutr. 2001 Jan;73(1):61-7 [11124751.001]
  • [Cites] Arch Intern Med. 2001 Aug 13-27;161(15):1857-62 [11493127.001]
  • [Cites] Curr Opin Lipidol. 2002 Feb;13(1):3-9 [11790957.001]
  • [Cites] J Neurochem. 2002 Jan;80(1):101-10 [11796748.001]
  • [Cites] Nutr Neurosci. 2002 Oct;5(5):291-309 [12385592.001]
  • [Cites] Neurology. 2002 Oct 22;59(8):1161-9 [12391343.001]
  • [Cites] Ann Neurol. 2002 Dec;52(6):793-801 [12447934.001]
  • [Cites] Am J Clin Nutr. 2002 Dec;76(6):1261-71 [12450892.001]
  • [Cites] Neurology. 2003 Mar 11;60(5):790-5 [12629235.001]
  • [Cites] Neurology. 2003 Jun 10;60(11):1761-6 [12796527.001]
  • [Cites] N Engl J Med. 2003 Jun 26;348(26):2599-608 [12826634.001]
  • [Cites] Arch Neurol. 2003 Aug;60(8):1059-64 [12925360.001]
  • [Cites] Nat Rev Drug Discov. 2004 Mar;3(3):205-14 [15031734.001]
  • [Cites] Parkinsonism Relat Disord. 2004 May;10 Suppl 1:S3-7 [15109580.001]
  • [Cites] Am J Epidemiol. 2004 Aug 15;160(4):368-75 [15286022.001]
  • [Cites] Am J Clin Nutr. 2004 Oct;80(4):1029-35 [15447916.001]
  • [Cites] Int J Epidemiol. 1989 Dec;18(4):858-67 [2621022.001]
  • [Cites] Neurosci Lett. 1990 Jan 1;108(1-2):36-42 [1689475.001]
  • [Cites] Epidemiology. 1993 May;4(3):218-28 [8512986.001]
  • [Cites] J Am Diet Assoc. 1993 Jul;93(7):790-6 [8320406.001]
  • [Cites] BMJ. 1995 Dec 2;311(7018):1457-60 [8520331.001]
  • [Cites] Am J Epidemiol. 1996 Sep 1;144(5):480-4 [8781463.001]
  • [Cites] Am J Health Promot. 1996 Sep-Oct;11(1):42-52; discussion 52-3 [10163450.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 May 27;94(11):5923-8 [9159176.001]
  • [Cites] Aging (Milano). 1997 Aug;9(4):241-57 [9359935.001]
  • [Cites] Mov Disord. 1998;13 Suppl 1:13-6 [9613713.001]
  • [Cites] N Engl J Med. 1998 Oct 8;339(15):1044-53 [9761807.001]
  • [Cites] Mov Disord. 1999 Jan;14(1):28-37 [9918341.001]
  • [Cites] Am J Clin Nutr. 1999 Feb;69(2):243-9 [9989687.001]
  • [Cites] Arthritis Rheum. 2005 Jan;52(1):283-9 [15641075.001]
  • [Cites] Brain Res Mol Brain Res. 2005 Mar 24;134(1):18-23 [15790526.001]
  • [Cites] Lancet Neurol. 2005 Jun;4(6):362-5 [15907740.001]
  • [Cites] Ann Neurol. 2005 Jun;57(6):927-30 [15929053.001]
  • [Cites] Am J Clin Nutr. 2005 Jul;82(1):163-73 [16002815.001]
  • [Cites] Ann Neurol. 2005 Nov;58(5):797-800 [16240356.001]
  • [Cites] Ann Neurol. 2005 Dec;58(6):963-7 [16240369.001]
  • [Cites] Ann Neurol. 2005 Dec;58(6):972-3 [16315277.001]
  • [Cites] J Nutr. 2006 Feb;136(2):466-72 [16424129.001]
  • [Cites] Acta Neurol Scand. 2006 Apr;113(4):278-81 [16542169.001]
  • [Cites] J Nutr. 2006 Apr;136(4):1021-6 [16549468.001]
  • [Cites] J Nutr. 2006 May;136(5):1341-6 [16614427.001]
  • [Cites] Ann Neurol. 2006 Jun;59(6):912-21 [16622828.001]
  • [Cites] Arch Intern Med. 2006 Jul 10;166(13):1403-9 [16832006.001]
  • [Cites] Circulation. 2006 Jul 11;114(2):160-7 [16818808.001]
  • [Cites] Am J Clin Nutr. 2000 Oct;72(4):912-21 [11010931.001]
  • (PMID = 17991663.001).
  • [ISSN] 0002-9165
  • [Journal-full-title] The American journal of clinical nutrition
  • [ISO-abbreviation] Am. J. Clin. Nutr.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / Z01 ES101986-02; United States / NINDS NIH HHS / NS / NS048517-03; United States / NINDS NIH HHS / NS / NS048517-01A2; United States / NINDS NIH HHS / NS / R01 NS048517; United States / NINDS NIH HHS / NS / R01 NS048517-01A2; United States / NINDS NIH HHS / NS / R01 NS048517-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0LVT1QZ0BA / Homocysteine
  • [Other-IDs] NLM/ NIHMS36654; NLM/ PMC2225168
  •  go-up   go-down


2. Bernabei R, Landi F, Onder G, Liperoti R, Gambassi G: Second and third generation assessment instruments: the birth of standardization in geriatric care. J Gerontol A Biol Sci Med Sci; 2008 Mar;63(3):308-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The systematic adoption of "second-generation" comprehensive geriatric assessment instruments, initiated with the Minimum Data Set (MDS) implementation in U.S. nursing homes, and continued with the uptake of related MDS instruments internationally, has contributed to the creation of large patient-level data sets.
  • In the present special article, we illustrate the potential of analyses using the MDS data to: (a) identify novel prognostic factors;.
  • (b) explore outcomes of interventions in relatively unselected clinical populations;.
  • The participants were assessed by trained staff using the MDS for Home Care, 2.0 version.
  • We argue that the harmonization by InterRAI of the MDS forms for different health settings, referred to as "the third generation of assessment," has produced the first scientific, standardized methodology in the approach to effective geriatric care.

  • MedlinePlus Health Information. consumer health - Home Care Services.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18375880.001).
  • [ISSN] 1079-5006
  • [Journal-full-title] The journals of gerontology. Series A, Biological sciences and medical sciences
  • [ISO-abbreviation] J. Gerontol. A Biol. Sci. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Hasselmann O, Blau N, Ramaekers VT, Quadros EV, Sequeira JM, Weissert M: Cerebral folate deficiency and CNS inflammatory markers in Alpers disease. Mol Genet Metab; 2010 Jan;99(1):58-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebral folate deficiency and CNS inflammatory markers in Alpers disease.
  • We describe a 3.5-year-old female with Alpers disease with a POLG genotype of p.A467T/p.G848S and with a lethal outcome.
  • Alpers disease, a neurodegenerative disease usually presents in the first years of life as a progressive encephalopathy with multifocal myoclonic seizures, developmental regression, cortical blindness and early death.
  • The underlying genetic defect has been attributed to mutations of the catalytic subunit of the mitochondrial DNA polymerase-gamma leading to an organ-specific mitochondrial DNA depletion syndrome with reduced activity of respiratory chain enzyme complexes in the brain and the liver.
  • A curative therapy is not available.
  • This case report of Alpers disease provides new insights into the pathophysiology of Alpers disease, where mitochondrial dysfunction in conjunction with inflammatory cytokines and blocking folate receptor autoantibodies may lead to a secondary cerebral folate deficiency syndrome.
  • The treatment of the latter provides relief to the patient without stopping the underlying disease.
  • [MeSH-minor] Amino Acid Substitution. Autoantibodies / blood. Autoantibodies / cerebrospinal fluid. Brain / metabolism. Brain / pathology. Carrier Proteins / immunology. Central Nervous System / metabolism. Central Nervous System / pathology. Child, Preschool. DNA-Directed DNA Polymerase / genetics. Fatal Outcome. Female. Folate Receptors, GPI-Anchored. Humans. Interferon-gamma / cerebrospinal fluid. Interleukin-6 / cerebrospinal fluid. Interleukin-8 / cerebrospinal fluid. Neopterin / cerebrospinal fluid. Receptors, Cell Surface / immunology

  • Genetic Alliance. consumer health - Neurodegeneration due to cerebral folate transport deficiency.
  • MedlinePlus Health Information. consumer health - Folic Acid.
  • Hazardous Substances Data Bank. FOLIC ACID .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • ORBi (University of Liege). Free full Text at ORBi .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19766516.001).
  • [ISSN] 1096-7206
  • [Journal-full-title] Molecular genetics and metabolism
  • [ISO-abbreviation] Mol. Genet. Metab.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / HD051880
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Carrier Proteins; 0 / Folate Receptors, GPI-Anchored; 0 / Inflammation Mediators; 0 / Interleukin-6; 0 / Interleukin-8; 0 / Receptors, Cell Surface; 670-65-5 / Neopterin; 82115-62-6 / Interferon-gamma; 935E97BOY8 / Folic Acid; EC 2.7.7.- / DNA polymerase gamma; EC 2.7.7.7 / DNA-Directed DNA Polymerase
  •  go-up   go-down


Advertisement
4. List A: Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes. Clin Lymphoma Myeloma; 2009;9 Suppl 3:S302-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes.
  • Lenalidomide is an immunomodulatory drug (IMiD) with erythropoietic activity in myelodysplastic syndromes (MDS) that is karyotype dependent.
  • The MDS-003 multicenter registration trial in deletion of chromosome 5q (del[5q]) showed that lenalidomide suppresses the del(5q) clone in patients who achieve transfusion independence and is a prerequisite for sustained restoration of effective erythropoiesis.
  • Long-term outcome data indicate that cytogenetic response to lenalidomide might confer a survival advantage compared with cytogenetic nonresponders, with a corresponding reduced risk for acute myeloid leukemia (AML) progression.
  • In lower-risk, transfusion-dependent patients with MDS without del(5q), lenalidomide has significant, albeit less erythropoietic, activity that could relate to dual effects on both the MDS clone and the bone marrow environment.
  • The most common adverse effects are neutropenia and thrombocytopenia, which occur early and with greater frequency in patients with del(5q), consistent with the drug's action to suppress the MDS clone.
  • Combination strategies are now in both MDS and AML that could further broaden the therapeutic potential of lenalidomide.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Myelodysplastic Syndromes / drug therapy. Thalidomide / analogs & derivatives
  • [MeSH-minor] Chromosome Deletion. Clinical Trials as Topic. Disease Progression. Humans. Immunosuppression. Karyotyping. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / genetics. Medical Oncology / methods. Medical Oncology / trends. Risk. Treatment Outcome


5. Dunphy CH: Evaluation of mast cells in myeloproliferative disorders and myelodysplastic syndromes. Arch Pathol Lab Med; 2005 Feb;129(2):219-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of mast cells in myeloproliferative disorders and myelodysplastic syndromes.
  • CONTEXT: Mast cells may be increased as a reactive mastocytosis in various hematologic disorders and malignant neoplasms, as well as in systemic mast cell disease (SMCD).
  • In addition, SMCD is frequently (45%) associated with myeloproliferative disorders (MPDs) (17%) and myelodysplastic syndromes (MDSs) (28%).
  • Thus, it has been suggested that SMCD may represent one aspect of a hematologic disorder that involves multiple bone marrow lineages.
  • DESIGN: A total of 55 MPDs or MDSs were reviewed, including 20 cytogenetically proven chronic myeloid leukemias, 6 essential thrombocythemias, 2 polycythemia veras, 21 cytogenetically proven MDSs, and 6 chronic myelomonocytic leukemias.
  • Cases of idiopathic myelofibrosis were not included due to lack of spicules.
  • The 2 polycythemia veras and 6 chronic myelomonocytic leukemias did not reveal increased or dyspoietic mast cells.
  • CONCLUSIONS: These findings indicate that MPDs (chronic myeloid leukemia and essential thrombocythemia) frequently contain neoplastic mast cells as the spectrum of abnormal bone marrow cells.
  • This feature, in conjunction with other parameters, may possibly be useful in the differential diagnosis of MPDs and MDSs.
  • [MeSH-major] Mast Cells / pathology. Myelodysplastic Syndromes / pathology. Myeloproliferative Disorders / pathology
  • [MeSH-minor] Cytodiagnosis / methods. Cytogenetic Analysis / methods. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. Polycythemia Vera / pathology. Retrospective Studies. Thrombocythemia, Essential / pathology


6. Martinez-Martin P, Deuschl G: Effect of medical and surgical interventions on health-related quality of life in Parkinson's disease. Mov Disord; 2007 Apr 30;22(6):757-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of medical and surgical interventions on health-related quality of life in Parkinson's disease.
  • We have reviewed the literature with a defined search strategy and collected 61 clinical trials, which have used HRQoL as a planned outcome parameter.
  • The articles were rated similarly as for the Task Force report of the Movement Disorder Society on interventions for Parkinson's disease (PD), but the relevant outcome parameter was HRQoL.
  • [MeSH-major] Health Status. Parkinson Disease / physiopathology. Parkinson Disease / therapy. Quality of Life
  • [MeSH-minor] Clinical Trials as Topic. Deep Brain Stimulation. Humans. Motor Activity. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Parkinson's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17343275.001).
  • [ISSN] 0885-3185
  • [Journal-full-title] Movement disorders : official journal of the Movement Disorder Society
  • [ISO-abbreviation] Mov. Disord.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 90
  •  go-up   go-down


7. Cristian A, Katz M, Cutrone E, Walker RH: Evaluation of acupuncture in the treatment of Parkinson's disease: a double-blind pilot study. Mov Disord; 2005 Sep;20(9):1185-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of acupuncture in the treatment of Parkinson's disease: a double-blind pilot study.
  • As many as 40% of patients with Parkinson's disease (PD) use some form of complementary medicine during the course of their illness, and many try acupuncture.
  • We performed a double-blind, randomized, pilot study comparing acupuncture to a control nonacupuncture procedure to determine the effects of acupuncture upon a variety of PD-associated symptoms.
  • Before and after treatment, patients were evaluated using the Motor subscale of the Unified Parkinson's Disease Rating Scale (UPDRS), the Parkinson's Disease Questionnaire (PDQ-39), and the Geriatric Depression Scale.
  • In the patients who received acupuncture, nonsignificant trends toward improvement were noted in the Activities of Daily Living score of the PDQ-39, the PDQ-39 Summary Index(c) 2005 Movement Disorder Society.
  • [MeSH-major] Acupuncture Therapy / methods. Parkinson Disease / therapy

  • MedlinePlus Health Information. consumer health - Acupuncture.
  • MedlinePlus Health Information. consumer health - Parkinson's Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Movement Disorder Society.
  • (PMID = 15884039.001).
  • [ISSN] 0885-3185
  • [Journal-full-title] Movement disorders : official journal of the Movement Disorder Society
  • [ISO-abbreviation] Mov. Disord.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


8. Sipahi T, Tavil B, Oksal A: Visceral leishmaniasis and pseudomonas septicemia associated with hemophagocytic syndrome and myelodysplasia in a Turkish child. Turk J Pediatr; 2005 Apr-Jun;47(2):191-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Visceral leishmaniasis and pseudomonas septicemia associated with hemophagocytic syndrome and myelodysplasia in a Turkish child.
  • An 18-month-old boy presented with fever, hepatosplenomegaly, jaundice, pancytopenia, hyperferritinemia, hypertriglyceridemia and evidence of hemophagocytosis and trilineage myelodysplasia in the bone marrow aspiration.


9. Scott BL, Storer BE, Greene JE, Hackman RC, Appelbaum FR, Deeg HJ: Marrow fibrosis as a risk factor for posttransplantation outcome in patients with advanced myelodysplastic syndrome or acute myeloid leukemia with multilineage dysplasia. Biol Blood Marrow Transplant; 2007 Mar;13(3):345-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Marrow fibrosis as a risk factor for posttransplantation outcome in patients with advanced myelodysplastic syndrome or acute myeloid leukemia with multilineage dysplasia.
  • Marrow fibrosis is considered a poor prognostic factor in patients with myelodysplastic syndrome (MDS).
  • The affect of fibrosis on outcomes after hematopoietic cell transplantation (HCT) in patients with MDS has not been examined.
  • We performed a retrospective analysis in 471 patients with MDS or acute myeloid leukemia with multilineage dysplasia arising from MDS, 113 with and 358 without marrow fibrosis, who received myeloablative allogeneic HCT.
  • However, among patients with advanced disease (int-2 or high-risk disease by the International Prognostic Scoring System), OS (P = .03), RFS (P = .04), and NRM (P = .04) were inferior when marrow fibrosis was present.
  • Given that marrow fibrosis is a poor prognostic factor for patients with MDS, and that it does not appear to affect outcome of transplantation in patients with earlier-stage disease but has a negative impact on outcome for patients with advanced disease, patients with earlier-stage MDS and marrow fibrosis might be considered for HCT earlier than their disease stage would normally dictate.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / complications. Myelodysplastic Syndromes / complications. Primary Myelofibrosis / mortality


10. Garcia-Manero G: Progress in myelodysplastic syndromes. Clin Lymphoma Myeloma; 2009;9 Suppl 3:S286-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progress in myelodysplastic syndromes.
  • During the past 5 years, we have witnessed an explosion in our understanding, classification, and number of therapeutic opportunities for patients with myelodysplastic syndromes (MDS).
  • These include the development of new histologic classifications, scoring systems, supportive care measures, and most importantly, effective treatments that are safe and can modify the natural history of this complex group of hematopoietic disorders.
  • In this brief review, and as part of the Leukemia 2008, Fourth International Conference, held in Houston during September 2008, I summarize some of the most important recent developments in the field of MDS and try to identify new problems and opportunities for patients and researchers in this area.


11. Shi JM, Huang H, Cai Z, Luo Y, Ye XJ, Zhang J, Li L, He JS, Xie WZ, Zheng WY, Meng XJ, Lin MF: [Study on unrelated donor allogeneic bone marrow transplantation with Bu-CY2 conditioning regimen for myelodysplastic syndrome]. Zhejiang Da Xue Xue Bao Yi Xue Ban; 2006 Mar;35(2):122-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study on unrelated donor allogeneic bone marrow transplantation with Bu-CY2 conditioning regimen for myelodysplastic syndrome].
  • OBJECTIVE: To evaluate the efficacy and safety of Bu-CY(2) conditioning regimen on allogeneic bone marrow transplantation (BMT) with unrelated donor for myelodysplastic syndrome.
  • Mycophenolate mofetil combined with cyclosporin A and methotrexate was used for prevention of acute graft-versus-host disease after transplantation.
  • Lipo prostaglandin E(1)was used in prophylactic regimen for hepatic veno-occlusive disease.
  • Disease-free survival in the six patients was 27 months.
  • CONCLUSION: Bu-CY(2) conditioning regimen on allogeneic bone marrow transplantation with unrelated donor is an effective therapy for patients with myelodysplastic syndrome.
  • [MeSH-major] Bone Marrow Transplantation. Busulfan / administration & dosage. Cyclophosphamide / administration & dosage. Myelodysplastic Syndromes / surgery. Transplantation Conditioning


12. Manabe M, Nakamura K, Nakamura J, Fukuyama T, Fukada E, Senzaki H, Ohta K: Acute myeloid leukemia with cuplike nuclei and intracytoplasmic inclusions following myelodysplastic syndrome. Int J Hematol; 2009 Jul;90(1):11-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloid leukemia with cuplike nuclei and intracytoplasmic inclusions following myelodysplastic syndrome.
  • [MeSH-major] Anemia, Refractory, with Excess of Blasts / pathology. Cell Nucleus / ultrastructure. Leukemia, Myeloid, Acute / pathology. Neoplasms, Second Primary / pathology

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2004 Oct;18(10):1591-8 [15343344.001]
  • (PMID = 19533272.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Vitamins; 12001-79-5 / Vitamin K; 1406-16-2 / Vitamin D; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


13. Zhang L, Qi JY, Zhang FK, Qiu LG: Detection of CD59-deficient granulocytes in a patient with advanced myelodysplastic syndrome. Chin Med J (Engl); 2009 Sep 5;122(17):2071-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of CD59-deficient granulocytes in a patient with advanced myelodysplastic syndrome.
  • [MeSH-major] Antigens, CD59 / immunology. Granulocytes / immunology. Myelodysplastic Syndromes / immunology

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19781399.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD59
  •  go-up   go-down


14. Stride M, Baqai T, Jawad AS: Hook sign and arthritis in refractory anaemia with ringed sideroblasts (myelodysplastic syndrome). Rheumatology (Oxford); 2009 Mar;48(3):320-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hook sign and arthritis in refractory anaemia with ringed sideroblasts (myelodysplastic syndrome).


15. Kang SY, Wasaka T, Shamim EA, Auh S, Ueki Y, Lopez GJ, Kida T, Jin SH, Dang N, Hallett M: Characteristics of the sequence effect in Parkinson's disease. Mov Disord; 2010 Oct 15;25(13):2148-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of the sequence effect in Parkinson's disease.
  • The sequence effect (SE) in Parkinson's disease (PD) is progressive slowing of sequential movements.
  • We also examined the correlation between the SE and clinical fatigue.
  • Levodopa alone, rTMS alone, and their combination did not alleviate the SE.
  • This study suggests that dopaminergic dysfunction and abnormal motor cortex excitability are not the relevant mechanisms for the SE.
  • Additionally, the SE is not a component of clinical fatigue.
  • Further work is needed to establish the physiology and clinical relevance of the SE.
  • © 2010 Movement Disorder Society.
  • [MeSH-major] Disease Progression. Movement / physiology. Parkinson Disease / physiopathology. Psychomotor Performance / physiology

  • MedlinePlus Health Information. consumer health - Parkinson's Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20669182.001).
  • [ISSN] 1531-8257
  • [Journal-full-title] Movement disorders : official journal of the Movement Disorder Society
  • [ISO-abbreviation] Mov. Disord.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / ZIA NS003031-08
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiparkinson Agents; 46627O600J / Levodopa
  • [Other-IDs] NLM/ NIHMS764347; NLM/ PMC4782591
  •  go-up   go-down


16. Benjamin PJ, Phillips R, Warren D, Salveson C, Hammerschlag R, Snider P, Haas M, Barrett R, Chapman T, Kaneko R, Martin M, Myer SN, Nedrow A, Niemiec C, O'Bryon D, Ochoa S, Peterson D, Weeks J, ACCAHC/OCCIM Task Force: Response to a proposal for an integrative medicine curriculum. J Altern Complement Med; 2007 Nov;13(9):1021-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to a proposal for an integrative medicine curriculum.
  • This discussion led to a formal process for responding to the issues raised by the paper.
  • This process led to a broad, cross-discipline agreement on important points to include in a response to the integrative medicine (IM) curriculum proposal.
  • (3) lack of recognition of the breadth of whole systems of health care;.
  • (4) omission of competencies related to collaboration between MDs and CAM professionals in patient care; and (5) omission of potential areas of partnership in IM education.
  • [MeSH-major] Clinical Competence. Complementary Therapies / education. Curriculum / standards. Education, Medical / standards. Interdisciplinary Communication. Quality Assurance, Health Care
  • [MeSH-minor] Academic Medical Centers / organization & administration. Clinical Medicine / education. Education, Medical, Continuing / standards. Education, Medical, Graduate / standards. Education, Medical, Undergraduate / standards. Health Services Needs and Demand. Humans. Practice Guidelines as Topic. United States

  • MedlinePlus Health Information. consumer health - Complementary and Integrative Medicine.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Altern Complement Med. 2008 Jun;14(5):454 [18564949.001]
  • (PMID = 18047450.001).
  • [ISSN] 1075-5535
  • [Journal-full-title] Journal of alternative and complementary medicine (New York, N.Y.)
  • [ISO-abbreviation] J Altern Complement Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


17. Dai E, Couriel D, Kim SK: Bilateral marginal keratitis associated with engraftment syndrome after hematopoietic stem cell transplantation. Cornea; 2007 Jul;26(6):756-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral marginal keratitis associated with engraftment syndrome after hematopoietic stem cell transplantation.
  • PURPOSE: To report the first case of bilateral marginal keratitis in the setting of engraftment syndrome in a patient who had undergone hematopoietic stem cell transplantation.
  • METHODS: A 63-year-old man with a history of myelodysplastic syndrome presented with a 5-day history of red eyes.
  • Two weeks before presentation, the patient had received a matched unrelated donor peripheral blood stem cell transplant and subsequently developed engraftment syndrome with a rapid white blood cell count recovery, noninfectious fever, skin rash, and shortness of breath.
  • Ocular bacterial and viral cultures were negative, and a conjunctival biopsy was negative for viral inclusions or ocular graft-versus-host disease.
  • CONCLUSIONS: Engraftment syndrome is notable for a rapid recovery of the white blood cell count after hematopoietic stem cell transplantation.
  • Patients who present with presumed conjunctivitis in the setting of autologous and allogeneic stem cell transplantation should be evaluated for engraftment syndrome-related marginal keratitis.
  • [MeSH-minor] Administration, Topical. Glucocorticoids / therapeutic use. Humans. Male. Middle Aged. Myelodysplastic Syndromes / therapy. Prednisolone / analogs & derivatives. Prednisolone / therapeutic use. Syndrome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Breathing Problems.
  • MedlinePlus Health Information. consumer health - Fever.
  • MedlinePlus Health Information. consumer health - Rashes.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17592333.001).
  • [ISSN] 0277-3740
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids; 8B2807733D / prednisolone acetate; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


18. Jayaraman A, Roberts KA, Yoon J, Yarmush DM, Duan X, Lee K, Yarmush ML: Identification of neutrophil gelatinase-associated lipocalin (NGAL) as a discriminatory marker of the hepatocyte-secreted protein response to IL-1beta: a proteomic analysis. Biotechnol Bioeng; 2005 Aug 20;91(4):502-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multidimensional scaling (MDS) of correlation distances between protein secretion levels revealed two protein pairs that are robustly co-secreted across the various cytokine stimulation conditions, suggesting shared regulatory pathways.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley Periodicals, Inc.
  • (PMID = 15918168.001).
  • [ISSN] 0006-3592
  • [Journal-full-title] Biotechnology and bioengineering
  • [ISO-abbreviation] Biotechnol. Bioeng.
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / 5R01-GM-65474; United States / CSR NIH HHS / RG / RG-01-0117
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acute-Phase Proteins; 0 / Biomarkers; 0 / Blood Proteins; 0 / Interleukin-1; 0 / Interleukin-6; 0 / LCN2 protein, human; 0 / Lipocalins; 0 / Proto-Oncogene Proteins
  •  go-up   go-down


19. Reis-Alves SC, Traina F, Saad ST, Metze K, Lorand-Metze I: The impact of several phenotypic features at diagnosis on survival of patients with myelodysplastic syndromes. Neoplasma; 2010;57(6):530-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of several phenotypic features at diagnosis on survival of patients with myelodysplastic syndromes.
  • Multiparametric flow cytometry is a useful co-criterion for diagnostic confirmation of MDS in patients with peripheral cytopenias and a normal karyotype.
  • Diagnosis of the patients (54) was made by WHO criteria using peripheral blood counts, bone marrow (BM) morphology and karyotype.
  • Flow cytometry was performed at diagnosis, and features obtained were compared to normal BM (24).
  • Our panel was sufficient to confirm the diagnosis of MDS and permitted to detect independent prognostic features.
  • [MeSH-major] Myelodysplastic Syndromes / mortality


20. Xiang YH, Su XL, Hu CP, Luo YQ, He RX: [A study of the related pathways of oxidative stress in chronic intermittent hypoxia rats and the effect of N-acetylcysteine]. Zhonghua Jie He He Hu Xi Za Zhi; 2010 Dec;33(12):912-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To study the relation of oxidative stress with systolic blood pressure (SBP) and renin-agiotensin system (RAS) in a rat model of chronic intermittent hypoxia (CIH), and to investigate the preventive effect and mechanism of N-acetylcysteine (NAC) in CIH-induced hypertension.
  • The levels of MDS and ox-LDL in serum showed a positive correlation with AngII in serum and kidney tissues respectively, but showed a negative correlation with Ang-(1-7) in serum and kidney tissues respectively.
  • All the data were not different between CIH2 and CIH3 groups (P>0.05).
  • [MeSH-minor] Animals. Blood Pressure. Male. Rats. Rats, Sprague-Dawley. Renin-Angiotensin System. Sleep Apnea, Obstructive / metabolism


21. Spinazzola A, Massa V, Hirano M, Zeviani M: Lack of founder effect for an identical mtDNA depletion syndrome (MDS)-associated MPV17 mutation shared by Navajos and Italians. Neuromuscul Disord; 2008 Apr;18(4):315-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of founder effect for an identical mtDNA depletion syndrome (MDS)-associated MPV17 mutation shared by Navajos and Italians.
  • Navajo neurohepatopathy is a hepato-cerebral variant of mitochondrial DNA depletion syndrome due to a specific mutation in MPV17, a gene located on human chromosome 2p.

  • MedlinePlus Health Information. consumer health - Mitochondrial Diseases.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18261905.001).
  • [ISSN] 0960-8966
  • [Journal-full-title] Neuromuscular disorders : NMD
  • [ISO-abbreviation] Neuromuscul. Disord.
  • [Language] eng
  • [Grant] Italy / Telethon / / GGP07019
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MAL protein, human; 0 / Membrane Transport Proteins; 0 / Myelin Proteins; 0 / Myelin and Lymphocyte-Associated Proteolipid Proteins; 0 / Proteolipids
  •  go-up   go-down


22. Nelson ME, Thurmes PJ, Hoyer JD, Steensma DP: A novel 5' ATRX mutation with splicing consequences in acquired alpha thalassemia-myelodysplastic syndrome. Haematologica; 2005 Nov;90(11):1463-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel 5' ATRX mutation with splicing consequences in acquired alpha thalassemia-myelodysplastic syndrome.
  • BACKGROUND AND OBJECTIVES: Acquired alpha thalassemia (hemoglobin H (HbH) disease) is a rare complication of neoplastic chronic myeloid disorders, especially myelodysplastic syndrome.
  • Acquired HbH has recently been associated with mutations in an X-linked gene, ATRX, previously linked to inherited ATR-X syndrome (alpha thalassemia-retardation-X linked).
  • DESIGN AND METHODS: A Swiss man with chronic myelomonocytic leukemia complicated by various autoimmune disorders and by strikingly microcytic, hypochromic anemia was analyzed for the presence of acquired HbH.
  • Plasmid vector cloning of patient ATRX cDNA demonstrated both exon 4 skipping and partial intron retention with activation of a cryptic splice site, both outcomes resulting in frameshifts with premature stop codon generation in exon 5 and near-decimation of ATRX expression in myeloid cells.
  • INTERPRETATION AND CONCLUSIONS: Intronic ATRX mutations with splicing consequences, uncommon in inherited ATR-X syndrome because of their devastating effect on expression of functional protein, should be routinely sought when undertaking molecular analysis of acquired HbH disease.
  • Detection of an acquired ATRX mutation can help support clonality in karyotypically normal ambiguous myeloid disorders with HbH.
  • [MeSH-major] 5' Flanking Region / genetics. DNA Helicases / genetics. Myelodysplastic Syndromes / genetics. Nuclear Proteins / genetics. Point Mutation / genetics. alpha-Thalassemia / genetics

  • Genetic Alliance. consumer health - Alpha-Thalassemia.
  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • Genetic Alliance. consumer health - Thalassemia.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16266892.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Databank-accession-numbers] RefSeq/ NM/ 000489
  • [Grant] United States / NCI NIH HHS / CA / K12 CA 90628
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / RNA Splice Sites; EC 3.6.4.- / DNA Helicases; EC 3.6.4.12 / ATRX protein, human
  •  go-up   go-down


23. Shah NM, Prajapati SG, Adesara RP, Patel AP: An analysis of 30 cases of myelodysplastic syndrome. Indian J Pathol Microbiol; 2009 Apr-Jun;52(2):206-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An analysis of 30 cases of myelodysplastic syndrome.
  • Myelodysplastic syndrome (MDS) is a clonal disorder of pluripotential stem cells of the bone marrow.
  • The purpose of the study was to obtain epidemiological data of MDS.
  • Thirty cases of MDS presented from April 1998 to May 2006 are included in this study.
  • Patients were symptomatic for a prolonged period before diagnosis could be reached (average 358.8 days).
  • A majority of the patients had MDS-refractory anemia (MDS-RA) or MDS-RA with excess blasts (MDS-RAEB-2) at presentation.
  • [MeSH-major] Blood Cell Count. Bone Marrow / pathology. Myelodysplastic Syndromes / epidemiology


24. Taher A, Cappellini MD, Vichinsky E, Galanello R, Piga A, Lawniczek T, Clark J, Habr D, Porter JB: Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol; 2009 Dec;147(5):752-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This retrospective analysis investigated the efficacy (based on change in serum ferritin levels) and safety of deferasirox >30 mg/kg per d in adult and paediatric patients with transfusion-dependent anaemias, including beta-thalassaemia, sickle cell disease and the myelodysplastic syndromes.
  • In total, 264 patients pooled from four clinical trials received doses of >30 mg/kg per d; median exposure to deferasirox >30 mg/kg per d was 36 weeks.
  • In the overall population there was a statistically significant median decrease in serum ferritin of 440 microg/l (P < 0.0001) from pre-dose-escalation to the time-of-analysis; significant decreases were also observed in adult and paediatric patients, as well as beta-thalassaemia patients.

  • Genetic Alliance. consumer health - Iron Overload.
  • MedlinePlus Health Information. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Blood Transfusion and Donation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2003 May 10;361(9369):1597-602 [12747879.001]
  • [Cites] J Clin Pathol. 1986 Mar;39(3):253-5 [3958215.001]
  • [Cites] N Engl J Med. 1994 Sep 1;331(9):574-8 [8047081.001]
  • [Cites] Blood. 1997 Feb 1;89(3):739-61 [9028304.001]
  • [Cites] Blood. 2006 May 1;107(9):3455-62 [16352812.001]
  • [Cites] Eur J Haematol. 2009 Jun;82(6):458-65 [19187278.001]
  • [Cites] Haematologica. 2006 Oct;91(10):1343-51 [17018383.001]
  • [Cites] Br J Haematol. 2007 Feb;136(3):501-8 [17233848.001]
  • [Cites] Blood. 2008 Jan 15;111(2):583-7 [17951527.001]
  • [Cites] Eur J Haematol. 2008 Feb;80(2):168-76 [18028431.001]
  • [Cites] Haematologica. 2006 Jul;91(7):873-80 [16818273.001]
  • (PMID = 19764988.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzoates; 0 / Iron Chelating Agents; 0 / Triazoles; 9007-73-2 / Ferritins; AYI8EX34EU / Creatinine; V8G4MOF2V9 / deferasirox
  • [Other-IDs] NLM/ PMC2779992
  •  go-up   go-down


25. Wells RA, Leber B, Buckstein R, Lipton JH, Hasegawa W, Grewal K, Yee K, Olney HJ, Larratt L, Vickars L, Tinmouth A: Iron overload in myelodysplastic syndromes: a Canadian consensus guideline. Leuk Res; 2008 Sep;32(9):1338-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Iron overload in myelodysplastic syndromes: a Canadian consensus guideline.
  • In December 2005, 11 Canadian hematologists met to develop an evidence-based clinical practice guideline that would address the diagnosis, monitoring, management, and rationale for the treatment of transfusional iron overload in patients with myelodysplastic syndromes (MDS).
  • Based on an extensive literature search and years of clinical experience, their mandate was to address common clinical practice questions, particularly why treat, whom to treat, when to initiate treatment, and how to treat iron overload in patients with MDS.
  • [MeSH-major] Blood Transfusion / adverse effects. Iron Chelating Agents / therapeutic use. Iron Overload / drug therapy. Myelodysplastic Syndromes / therapy


26. Fabre C, Grosjean J, Tailler M, Boehrer S, Adès L, Perfettini JL, de Botton S, Fenaux P, Kroemer G: A novel effect of DNA methyltransferase and histone deacetylase inhibitors: NFkappaB inhibition in malignant myeloblasts. Cell Cycle; 2008 Jul 15;7(14):2139-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant myeloblasts arising in high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are characterized by the constitutive activation of the anti-apoptotic transcription factor NFkappaB.
  • We found that DNA methyltransferase (DNMT) inhibitors (such as azacytidine and 5-aza-2'-deoxycytidine) and histone deacetylase (HDAC) inhibitors (such as trichostatin and valproic acid) efficiently induced apoptosis in the P39 MDS/AML cell line, correlating with an inhibition of NFkappaB (which translocated from the nucleus to the cytoplasm).
  • This effect was obtained rapidly, within a few hours, suggesting that it was not due to epigenetic reprogramming.
  • [MeSH-minor] Azacitidine / pharmacology. Cell Line, Tumor. Female. Humans. Hydroxamic Acids / pharmacology. I-kappa B Kinase / metabolism. Leukemia, Myeloid, Acute / metabolism. Leukemia, Myeloid, Acute / pathology. Male. Middle Aged. Valproic Acid / pharmacology

  • Hazardous Substances Data Bank. AZACITIDINE .
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18641459.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 0 / NF-kappa B; 3X2S926L3Z / trichostatin A; 614OI1Z5WI / Valproic Acid; EC 2.1.1.37 / DNA (Cytosine-5-)-Methyltransferase; EC 2.7.11.10 / I-kappa B Kinase; M801H13NRU / Azacitidine
  •  go-up   go-down


27. Sato K, Lewandowski RJ, Bui JT, Omary R, Hunter RD, Kulik L, Mulcahy M, Liu D, Chrisman H, Resnick S, Nemcek AA Jr, Vogelzang R, Salem R: Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol; 2006 Jul-Aug;29(4):522-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In Canada and Europe, yttrium-90 microspheres (TheraSphere); MDS Nordion, Ottawa, Canada) are a primary treatment option for primary and secondary hepatic malignancies.
  • We present data from 30 patients with hepatocellular carcinoma (HCC) and metastatic liver disease treated with TheraSphere from a single academic institution to evaluate the angiographically evident embolization that follows treatment.
  • The incidence of postembolization syndrome (PES) was determined as well as objective tumor response rates by the World Health Organization (WHO), Response Evaluation Criteria in Solid Tumors (RECIST), and European Association for the Study of the Liver (EASL) criteria.
  • The pretreatment and posttreatment angiograms could not be correctly identified on average more than 43% of the time (p = 0.0004).
  • This treatment method does not result in macroscopic embolization of the hepatic arteries, thereby maintaining hepatic tissue perfusion.


28. Yamamoto K, Ito M, Minagawa K, Urahama N, Sada A, Okamura A, Matsui T: A der(13)t(7;13)(p13;q14) with monoallelic loss of RB1 and D13S319 in myelodysplastic syndrome. Cancer Genet Cytogenet; 2005 Oct 15;162(2):160-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A der(13)t(7;13)(p13;q14) with monoallelic loss of RB1 and D13S319 in myelodysplastic syndrome.
  • Deletions or translocations of chromosome band 13q14, the locus of the retinoblastoma gene (RB1), have been observed in a variety of hematological malignancies including myelodysplastic syndrome (MDS).
  • We describe here a novel unbalanced translocation der(13)t(7;13)(p13;q14) involving 13q14 in a patient with MDS.
  • A 66-year-old woman was diagnosed as having MDS, refractory anemia with excess of blasts (RAEB-1) because of 7.4% blasts and trilineage dysplasia in the bone marrow cells.
  • Considering other reported cases, our results indicate that submicroscopic deletions accompanying 13q14 translocations are recurrent cytogenetic aberrations in MDS.
  • The RB1 gene or another tumor suppressor gene in the vicinity of D13S319, or both, may be involved in the pathogenesis of MDS with 13q14 translocations by monoallelic deletion.
  • [MeSH-major] Chromosome Deletion. Chromosomes, Human, Pair 13. Chromosomes, Human, Pair 7. Myelodysplastic Syndromes / genetics. Retinoblastoma Protein / genetics. Translocation, Genetic


29. Morgan MA, Reuter CW: Molecularly targeted therapies in myelodysplastic syndromes and acute myeloid leukemias. Ann Hematol; 2006 Mar;85(3):139-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecularly targeted therapies in myelodysplastic syndromes and acute myeloid leukemias.
  • Although there has been significant progress in acute myeloid leukemia (AML) treatment in younger adults during the last decade, standard induction therapy still fails to induce remission in up to 40% of AML patients.
  • Additionally, relapses are common in 50-70% of patients who achieve a complete remission, and only 20-30% of patients enjoy long-term disease-free survival.
  • The natural history of myelodysplastic syndrome (MDS) is variable, with about half of the patients dying from cytopenic complications, and an additional 20-30% transforming to AML.
  • The advanced age of the majority of MDS patients limits the therapeutic strategies often to supportive care.
  • Presented here is an overview of molecularly targeted therapies currently being tested in AML and MDS patients, with a focus on FMS-like tyrosine kinase 3 inhibitors, farnesyltransferase inhibitors, antiangiogenesis agents, DNA hypomethylation agents, and histone deacetylase inhibitors.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Enzyme Inhibitors / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Myelodysplastic Syndromes / drug therapy
  • [MeSH-minor] Age Factors. Animals. Cell Proliferation / drug effects. DNA Methylation / drug effects. Disease-Free Survival. Histone Acetyltransferases / antagonists & inhibitors. Humans. Neovascularization, Pathologic / drug therapy. Neovascularization, Pathologic / metabolism. Protein Processing, Post-Translational / drug effects. Receptor, Macrophage Colony-Stimulating Factor / antagonists & inhibitors. Receptor, Macrophage Colony-Stimulating Factor / metabolism. Remission Induction / methods


30. Miller JL: Glycoprotein analysis for the diagnostic evaluation of platelet disorders. Semin Thromb Hemost; 2009 Mar;35(2):224-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Congenital deficiencies or functional abnormalities in platelet glycoproteins may produce serious bleeding disorders such as Glanzmann thrombasthenia or Bernard-Soulier syndrome.
  • Other hematologic disorders, such as Fanconi anemia and various myelodysplastic syndromes, may also be associated with abnormalities in platelet glycoproteins.
  • The application of platelet glycoprotein analysis to a wide range of clinical disorders is reviewed in this article.
  • [MeSH-major] Blood Platelet Disorders / blood. Blood Platelet Disorders / diagnosis. Glycoproteins / analysis

  • Genetic Alliance. consumer health - Platelet Disorders.
  • MedlinePlus Health Information. consumer health - Platelet Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19408195.001).
  • [ISSN] 1098-9064
  • [Journal-full-title] Seminars in thrombosis and hemostasis
  • [ISO-abbreviation] Semin. Thromb. Hemost.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glycoproteins
  • [Number-of-references] 56
  •  go-up   go-down


31. Castro-Malaspina H, Jabubowski AA, Papadopoulos EB, Boulad F, Young JW, Kernan NA, Perales MA, Small TN, Hsu K, Chiu M, Heller G, Collins NH, Jhanwar SC, van den Brink M, Nimer SD, O'Reilly RJ: Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings. Biol Blood Marrow Transplant; 2008 Apr;14(4):458-68
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings.
  • From 1985 to 2004, 49 patients with advanced myelodysplastic syndromes (MDS) (> or =5% blasts) or acute myeloid leukemia (AML) transformed from MDS underwent T cell depleted bone marrow or peripheral blood hematopoietic stem cell transplantation (HSCT) from HLA-identical siblings following conditioning with a myeloablative regimen that included total body irradiation (44 patients) or busulfan (5 patients).
  • Thirty-six patients received chemotherapy (3 low dose and 33 induction doses) before conditioning, and 13 patients did not receive any chemotherapy.
  • Prior to transplantation, 22 of the 36 treated patients were in hematologic remission; 4 were in a second refractory cytopenia phase (26 responders); 8 had failed to achieve remission; and 2 of the responders had progression or relapse of their MDS (10 failures).
  • No post-transplantation pharmacologic prophylaxis for graft-versus-host disease (GVHD) was given.
  • The disease free survival (DFS) was 50%, 15% and 0% in each group respectively (P=.0008).
  • In multivariate analysis, disease status before cytoreduction remained highly correlated with DFS (P<.001).
  • These results indicate that patients with advanced MDS who achieve and remain in remission or a second refractory cytopenia phase with chemotherapy before conditioning can achieve successful long-term remissions following a myeloablative T cell depleted allogeneic HSCT.
  • [MeSH-major] HLA Antigens / immunology. Lymphocyte Depletion. Myelodysplastic Syndromes / therapy. Stem Cell Transplantation / methods. T-Lymphocytes / immunology. Transplantation, Isogeneic / methods
  • [MeSH-minor] Adolescent. Adult. Disease-Free Survival. Graft vs Host Disease / prevention & control. Humans. Middle Aged. Remission Induction. Retrospective Studies. Siblings. Transplantation Conditioning / methods. Treatment Outcome. Whole-Body Irradiation

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18342789.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA023766; United States / NCI NIH HHS / CA / P30 CA008748; United States / NHLBI NIH HHS / HL / R01 HL088134
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA Antigens
  • [Other-IDs] NLM/ NIHMS43830; NLM/ PMC4498391
  •  go-up   go-down


32. Hui CH, Horvath N, Lewis I, To LB, Szabo F: Outcome of patients with myelodysplastic syndromes: experience from a single institution in South Australia. Intern Med J; 2008 Nov;38(11):824-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of patients with myelodysplastic syndromes: experience from a single institution in South Australia.
  • AIMS: To study disease characteristics of adult patients with myelodysplastic syndromes (MDS) in South Australia and to analyse their outcome and survival.
  • METHODS: One hundred and eight adult patients with confirmed MDS from marrow biopsies in the 76-month period before April 2006 were retrospectively included in an MDS database.
  • RESULTS: The median age at diagnosis of this cohort was 70 years, with skewing of refractory anaemia with excess blasts and refractory cytopenia with multilineage dysplasia in the younger patients.
  • Median survival was 48 months, and secondary transformation to acute myeloid leukaemia was seen in 27%.
  • Survival, according to the World Health Organization subtypes in ascending order, was refractory anaemia with excess blasts, refractory anaemia, refractory anaemia with ringed sideroblast, refractory cytopenia with multilineage dysplasia and del(5q).
  • The International Prognostic Scoring System score stratified MDS patients into different risk groups and effectively discriminated significantly different survivals, ranging from a median 4 months for high-risk patients to 72 months for low-risk patients.
  • CONCLUSION: An MDS database provides useful information regarding the disease characteristics and survival of MDS patients in South Australia and confirms the prognostic usefulness of the International Prognostic Scoring System.
  • [MeSH-major] Hospitals / trends. Myelodysplastic Syndromes / mortality. Myelodysplastic Syndromes / therapy


33. Holley CD, Lee PP: Primary care provider views of the current referral-to-eye-care process: focus group results. Invest Ophthalmol Vis Sci; 2010 Apr;51(4):1866-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Purpose. To understand the barriers facing primary care providers (PCPs), including nurse practitioners (NPs) and physician assistants (PAs), in the current referral-to-eye-care process and to solicit suggestions from PCPs on how to improve the current referral system.
  • Methods. Four focus groups were conducted with a total of 17 PCPs: two groups with physicians (MDs): one in a rural setting and one in an academic medical center setting and one group of NPs and one of PAs, both in an academic setting.
  • Suggestions made in all groups on ways to improve the current referral system included (1) implementing electronic medical records (EMRs), (2) receiving better communication/feedback from ECPs, (3) having ophthalmologists hold clinic days in primary care facilities, and (4) performing retinal scans in primary care clinics.
  • We found few differences between the opinions of MDs and those of NPs and PAs.
  • Conclusions. PCPs desire change(s) in the current referral-to-eye-care system.
  • Implementing specific suggestions, such as modernizing medical record systems, may help to increase eye care utilization among patients at high risk for advancing eye disease and vision loss.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19875660.001).
  • [ISSN] 1552-5783
  • [Journal-full-title] Investigative ophthalmology & visual science
  • [ISO-abbreviation] Invest. Ophthalmol. Vis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


34. Kümpers P, Koenecke C, Hecker H, Hellpap J, Horn R, Verhagen W, Buchholz S, Hertenstein B, Krauter J, Eder M, David S, Göhring G, Haller H, Ganser A: Angiopoietin-2 predicts disease-free survival after allogeneic stem cell transplantation in patients with high-risk myeloid malignancies. Blood; 2008 Sep 1;112(5):2139-48
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiopoietin-2 predicts disease-free survival after allogeneic stem cell transplantation in patients with high-risk myeloid malignancies.
  • The angiopoietin/Tie ligand-receptor system is an essential regulator of this process.
  • We evaluated whether circulating angiopoietin-2 (Ang-2) is a predictor for the probability of disease-free survival (DFS) in allogeneic hematopoietic stem cell transplantation (allo-HSCT) for high-risk acute myeloid leukemia or myelodysplastic syndrome.
  • Ang-2 was measured by enzyme-linked immunosorbent assay in serum from 20 healthy controls and 90 patients with acute myeloid leukemia or myelodysplastic syndrome before conditioning for HSCT.
  • Because few predictors for DFS exist in the setting of allo-HSCT, Ang-2 may be used as a readily available powerful biomarker to pre-estimate DFS and may open new perspectives for risk-adapted treatment of high-risk myeloid malignancies.
  • [MeSH-major] Angiopoietin-2 / blood. Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / blood. Leukemia, Myeloid, Acute / therapy. Myelodysplastic Syndromes / blood. Myelodysplastic Syndromes / therapy
  • [MeSH-minor] Adult. Aged. Biomarkers / blood. Case-Control Studies. Disease-Free Survival. Female. Humans. Male. Middle Aged. Models, Biological. Neovascularization, Pathologic. Prognosis. Regression Analysis. Risk Factors. Transplantation, Homologous


35. Della Porta MG, Malcovati L, Invernizzi R, Travaglino E, Pascutto C, Maffioli M, Gallì A, Boggi S, Pietra D, Vanelli L, Marseglia C, Levi S, Arosio P, Lazzarino M, Cazzola M: Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. Leukemia; 2006 Apr;20(4):549-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome.
  • Erythroid dysplasia is the pathologic hallmark of myelodysplastic syndromes (MDS).
  • To develop a quantitative flow-cytometry approach to its evaluation, we analyzed the expression of CD71, CD105, cytosolic H-ferritin (HF), cytosolic L-ferritin (LF) and mitochondrial ferritin (MtF) in erythroblasts from 104 MDS patients, 69 pathologic control patients and 19 healthy subjects.
  • Compared with pathologic and healthy controls, MDS patients had higher expression of HF (P < 0.001) and CD105 (P < 0.001), and lower expression of CD71 (P < 0.001).
  • MtF was specifically detected in MDS with ringed sideroblasts, and there was a close relationship between its expression and Prussian blue staining (r = 0.89, P < 0.001).
  • In vitro cultures of myelodysplastic hematopoietic progenitors showed that both HF and MtF were expressed at a very early stage of erythroid differentiation, and that MtF expression is specifically related to mitochondrial iron loading.
  • A classification function based on expression levels of HF, CD71 and CD105 allowed us to correctly classify > 95% of MDS patients.
  • This flow-cytometry approach provides an accurate quantitative evaluation of erythroid dysplasia and allows a reliable diagnosis of sideroblastic anemia, and may therefore be a useful tool in the work-up of patients with MDS.
  • [MeSH-major] Erythroid Cells / pathology. Flow Cytometry / methods. Myelodysplastic Syndromes / pathology

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16498394.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] Italy / Telethon / / GP0075Y01
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD34; 0 / CD71 antigen; 0 / ENG protein, human; 0 / Endoglin; 0 / Receptors, Cell Surface; 0 / Receptors, Transferrin; 9007-73-2 / Ferritins; 9013-31-4 / Apoferritins
  •  go-up   go-down


36. Karargyris A, Bourbakis N: Wireless capsule endoscopy and endoscopic imaging: a survey on various methodologies presented. IEEE Eng Med Biol Mag; 2010 Jan-Feb;29(1):72-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although WCE has the advantage of investigating the whole digestive system, the viewing and evaluation of each WCE video is a time-consuming process (2-3 h) for MD gastroenterologists.
  • This makes the WCE methodology not widely efficient and acceptable by MDs.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20176525.001).
  • [ISSN] 1937-4186
  • [Journal-full-title] IEEE engineering in medicine and biology magazine : the quarterly magazine of the Engineering in Medicine & Biology Society
  • [ISO-abbreviation] IEEE Eng Med Biol Mag
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


37. Liao C, Yang X, Xu ZP, Huang YN, Wu SQ, Chen JS, Li Y, Tang XW, Wu JY: [Results of unrelated umbilical cord blood stem cell transplantation for 65 patients in China]. Zhonghua Er Ke Za Zhi; 2006 Mar;44(3):220-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: ALL (acute lymphocytic leukemia) cord blood units were obtained from full term normal vaginal and cesarean deliveries in Guangzhou Women and Infants Hospital.
  • Event-free survival and graft versus host disease (GVHD) were provided by transplant centers.
  • RESULTS: Out of 65 patients who received unrelated cord blood stem cell transplant, 49 patients were diagnosed as having malignant diseases [including 23 with ALL, 16 with AML (acute myeloid leukemia), 7 with CML (chronic myelogenous leukemia), 3 with lymphoma and one with MDS (myelodysplastic syndrome)], 16 patients had non-malignant disease.
  • Fifty patients had engraftment (ANC > 5.0 x 10(8)) after a median time of 17 (range 7 to 44) days after transplant, while an autologous hematopoietic reconstitution was observed in 6 patients; 24 patients died of severe pneumonia (n = 8), acute GVHD (n = 4), or sepsis (n = 12) and the disease-free survival probability was 61%.
  • [MeSH-major] Cord Blood Stem Cell Transplantation / methods. Leukemia / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. China. Disease-Free Survival. Female. Graft vs Host Disease / etiology. Graft vs Host Disease / mortality. Humans. Infant. Male. Retrospective Studies. Survival Rate. Transplantation, Homologous. Treatment Outcome. Young Adult


38. Steidl C, Steffens R, Gassmann W, Hildebrandt B, Hilgers R, Germing U, Trümper L, Haase D: Adequate cytogenetic examination in myelodysplastic syndromes: analysis of 529 patients. Leuk Res; 2005 Sep;29(9):987-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adequate cytogenetic examination in myelodysplastic syndromes: analysis of 529 patients.
  • In myelodysplastic syndromes (MDS), the karyotype is one of the most significant prognostic markers with profound impact on differential diagnosis and therapeutic decisions.
  • In a retrospective study, we examined karyotypes of bone marrow specimens of an oligocentric cohort comprising 529 patients with MDS to address the question how many metaphases need to be analyzed to detect even small cell clones with an appropriate expenditure.
  • In summary, our data suggest the examination of at least 20 metaphases in MDS.
  • [MeSH-major] Chromosome Aberrations. Myelodysplastic Syndromes / genetics


39. Tamura K, Kanazawa T, Suzuki M, Koitabashi M, Ogawa C, Morikawa A: Successful rapid discontinuation of immunosuppressive therapy at molecular relapse after allogeneic bone marrow transplantation in a pediatric patient with myelodysplastic syndrome. Am J Hematol; 2006 Feb;81(2):139-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful rapid discontinuation of immunosuppressive therapy at molecular relapse after allogeneic bone marrow transplantation in a pediatric patient with myelodysplastic syndrome.
  • The success of allogeneic bone marrow transplantation (allo-BMT) in children with myelodysplastic syndrome (MDS) is mainly affected by relapse.
  • The role of additional immunotherapy for pediatric patients with MDS relapsing after allo-BMT remains to be established.
  • Because immunotherapy is generally more effective for patients who bear a low tumor burden, monitoring of minimal residual diseases (MRD) is essential for early diagnosis at molecular relapse.
  • We report here that a patient with relapsed MDS after allo-BMT was successfully treated by the rapid discontinuation of immunosuppressive therapy at molecular relapse while monitoring Wilms tumor (WT1) gene expression levels.
  • [MeSH-major] Bone Marrow Transplantation / methods. Immunosuppressive Agents / therapeutic use. Myelodysplastic Syndromes / therapy. Neoplasm, Residual / diagnosis


40. Assi H, Missenard G, Terrier P, Le Pechoux C, Bonvalot S, Vanel D, Meric JB, Tursz T, Lecesne A: Intensive induction chemotherapy without methotrexate in adult patients with localized osteosarcoma: results of the Institut Gustave-Roussy phase II trial. Curr Oncol; 2010 Nov;17(6):23-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To improve outcomes in localized osteosarcoma and to reduce the duration of preoperative chemotherapy, we conducted a phase ii trial assessing the efficacy of an intensive protracted regimen without methotrexate (api-ai regimen) in adolescent and adult patients with newly diagnosed disease.
  • Two secondary hematologic malignancies occurred: 1 acute myelocytic leukemia (M5) in a poor responder with concomitant relapse, and 1 myelodysplastic syndrome in a patient achieving ghr.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21151406.001).
  • [ISSN] 1718-7729
  • [Journal-full-title] Current oncology (Toronto, Ont.)
  • [ISO-abbreviation] Curr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2993436
  • [Keywords] NOTNLM ; Induction chemotherapy / osteosarcoma
  •  go-up   go-down


41. Ashley N, Adams S, Slama A, Zeviani M, Suomalainen A, Andreu AL, Naviaux RK, Poulton J: Defects in maintenance of mitochondrial DNA are associated with intramitochondrial nucleotide imbalances. Hum Mol Genet; 2007 Jun 15;16(12):1400-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Defects in mtDNA maintenance range from fatal multisystem childhood diseases, such as Alpers syndrome, to milder diseases in adults, including mtDNA depletion syndromes (MDS) and familial progressive external ophthalmoplegia (AdPEO).
  • We have developed an in vitro system to measure incorporation of radiolabelled dNTPs into mitochondria of saponin permeabilized cells.
  • We observed reduced incorporation of exogenous alpha (32)P-dTTP in fibroblasts from a patient with Alpers syndrome associated with the A467T substitution in POLG, a patient with dGK mutations, and a patient with mtDNA depletion of unknown origin compared to controls.
  • [MeSH-minor] Cell Membrane Permeability. DNA Helicases / genetics. DNA Helicases / metabolism. DNA-Directed DNA Polymerase / genetics. DNA-Directed DNA Polymerase / metabolism. Deoxycytosine Nucleotides / metabolism. Humans. Mitochondrial Proteins. Models, Biological. Mutation. Phosphorus Radioisotopes. Syndrome. Thymidine Kinase / genetics. Thymidine Kinase / metabolism. Thymine Nucleotides / metabolism

  • MedlinePlus Health Information. consumer health - Mitochondrial Diseases.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17483096.001).
  • [ISSN] 0964-6906
  • [Journal-full-title] Human molecular genetics
  • [ISO-abbreviation] Hum. Mol. Genet.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0500695
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Mitochondrial; 0 / Deoxycytosine Nucleotides; 0 / Deoxyribonucleotides; 0 / Mitochondrial Proteins; 0 / Phosphorus Radioisotopes; 0 / Thymine Nucleotides; 2056-98-6 / 2'-deoxycytidine 5'-triphosphate; EC 2.7.1.- / thymidine kinase 2; EC 2.7.1.21 / Thymidine Kinase; EC 2.7.7.- / POLG protein, human; EC 2.7.7.7 / DNA-Directed DNA Polymerase; EC 3.6.4.- / DNA Helicases; EC 3.6.4.12 / C10ORF2 protein, human; QOP4K539MU / thymidine 5'-triphosphate
  •  go-up   go-down


42. Kaklamani VG, Tzonou A, Kaklamanis PG: Behçet's disease associated with malignancies. Report of two cases and review of the literature. Clin Exp Rheumatol; 2005 Jul-Aug;23(4 Suppl 38):S35-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Behçet's disease associated with malignancies. Report of two cases and review of the literature.
  • OBJECTIVE: To investigate the incidence of malignancies in a cohort of Behçet's disease patients and review the world literature.
  • Furthermore, we performed a MEDLINE search from 1970 through 2003, as well as, a search in the proceedings of international conferences for cases of malignancies associated with Behçet's disease.
  • RESULTS: Two of our 128 patients with Behçet's disease were found to have solid tumors.
  • In the world literature 112 cases of malignancies associated with Behçet's disease were found: Sixty five cases were of male patients and 46 of female with 1 case of unknown gender.
  • The solid malignancies associated with Behçet's disease included cases of bladder, breast, uterus, thyroid and stomach cancer, whereas haematological malignancies included leukemia, myelodysplastic syndrome, lymphoma, multiple myeloma, Hodgkin's disease and lymphosarcoma.
  • The treatment administered in these patients with their disease is also reported.
  • CONCLUSION: The age standardized rate of cancer in our population was lower than that of the general population in Greece, although the difference was not statistically significant.
  • However, there is discrepancy in the world literature and the possibility of development of malignancies in Behçet's disease patients should not be ignored.
  • [MeSH-major] Adenocarcinoma / complications. Behcet Syndrome / complications. Kidney Neoplasms / complications. Lung Neoplasms / complications


43. Chen BA, Zhao HH, Gao C, Shao ZY, Xia GH, Dohner K: [Effects of sodium valproate on proliferation and apoptosis of human myelodysplastic syndromes cell line MUTZ-1]. Ai Zheng; 2007 Dec;26(12):1323-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effects of sodium valproate on proliferation and apoptosis of human myelodysplastic syndromes cell line MUTZ-1].
  • BACKGROUND & OBJECTIVE: Myelodysplastic syndromes (MDS) are heterogeneous disorders with the expansion of malignant clones.
  • No satisfactory treatment for MDS is available.
  • This study was to investigate the effects of VPA on the proliferation of MDS cell line MUTZ-1, and explore possible mechanisms.
  • Cell morphology was observed under microscope and transmission electron microscope.
  • When treated with 4 mmol/L VPA for 72 h, typical apoptotic morphologic features appeared in MUTZ-1 cells: condensation of cells and nuclear chromatin, disintegration of nuclear chromatin, and apoptotic bodies were observed under microscope; aggregation and margination of apoptotic nuclear chromatin, cytoplasm condensation, and irregular chromatin masses were observed under transmission electron microscope.
  • [MeSH-major] Apoptosis / drug effects. Cell Proliferation / drug effects. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Myelodysplastic Syndromes / pathology. Valproic Acid / pharmacology


44. Greenberg PL: Current therapeutic approaches for patients with myelodysplastic syndromes. Br J Haematol; 2010 Jul;150(2):131-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current therapeutic approaches for patients with myelodysplastic syndromes.
  • The myelodysplastic syndromes (MDS) are a heterogeneous spectrum of disorders requiring selective therapy based on patients' specific clinical features, predominantly their prognostic subgroups, age and performance status.
  • Guidelines for management of patients with MDS have been generated by a number of national panels.
  • This review focuses on evidence-based data supporting therapeutic approaches, which have also been recommended by the US National Comprehensive Cancer Network MDS Panel, with discussion of accessibility of recommended drugs in the US and in other countries.
  • For lower risk disease (International Prognostic Scoring System Low and Intermediate-1) therapy is aimed at haematological improvement whereas for higher risk disease (Intermediate-2 and High) treatment focuses on altering disease natural history.
  • Recent information regarding additional clinical and biological features has provided useful parameters for assessing disease prognosis that aid risk-based management decisions.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Myelodysplastic Syndromes / drug therapy


45. Unnikrishnan V, Dutta TK, Badhe BA, Bobby Z, Panigrahi AK: Clinico-aetiologic profile of macrocytic anemias with special reference to megaloblastic anemia. Indian J Hematol Blood Transfus; 2008 Dec;24(4):155-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE OF STUDY: This study was conducted to study the clinical and laboratory parameters in patients with macrocytic anemia and to determine the etiology of macrocytic anemia with special reference to megaloblastic anemia.
  • Three patients (mean age 55 years) with a megaloblastic marrow did not respond to vitamin replacement and were found to have myelodysplastic syndrome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 1978 May;31(5):493-8 [649776.001]
  • [Cites] Arch Intern Med. 1979 Jan;139(1):47-50 [760683.001]
  • [Cites] Med Clin North Am. 1992 May;76(3):581-97 [1578958.001]
  • [Cites] N Engl J Med. 1988 Jun 30;318(26):1720-8 [3374544.001]
  • [Cites] Am Fam Physician. 1996 Jan;53(1):155-62 [8546042.001]
  • [Cites] Am J Med. 2002 Apr 1;112(5):413-6 [11904118.001]
  • [Cites] JAMA. 1964 Sep 28;189:997-9 [14188889.001]
  • [Cites] Ann Intern Med. 1973 May;78(5):677-83 [4711772.001]
  • [Cites] Clin Lab Haematol. 1984;6(1):1-7 [6734095.001]
  • [Cites] Blood. 1983 Apr;61(4):624-7 [6831032.001]
  • [Cites] Acta Med Scand. 1981;209(4):319-22 [7234509.001]
  • [Cites] JAMA. 1981 Mar 20;245(11):1144-6 [7463640.001]
  • [Cites] Postgrad Med. 1995 May;97(5):171-2, 175-7, 181-4 passim [7753741.001]
  • [Cites] BMJ. 1997 Feb 8;314(7078):430-3 [9040391.001]
  • [Cites] Am J Med Sci. 2000 Jun;319(6):343-52 [10875288.001]
  • (PMID = 23100955.001).
  • [ISSN] 0971-4502
  • [Journal-full-title] Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
  • [ISO-abbreviation] Indian J Hematol Blood Transfus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3475427
  • [Keywords] NOTNLM ; Bone marrow disorders / Macrocytic anemia / Megaloblastic anemia / Myelodysplastic syndrome / Non-megaloblastic macrocytic anemia
  •  go-up   go-down


46. Bross MH, Soch K, Smith-Knuppel T: Anemia in older persons. Am Fam Physician; 2010 Sep 1;82(5):480-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • About one third of persons have anemia secondary to a nutritional deficiency, one third have anemia caused by chronic inflammation or chronic kidney disease, and one third have unexplained anemia.
  • Anemia of chronic inflammation or chronic kidney disease may respond to treatment of the underlying disease and selective use of erythropoiesis-stimulating agents.
  • Occasionally, anemia may be caused by less common but potentially treatable conditions, such as autoimmune hemolytic anemia, malignancy, or myelodysplastic syndrome.

  • Genetic Alliance. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Anemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IRON COMPOUNDS .
  • Hazardous Substances Data Bank. FOLIC ACID .
  • Hazardous Substances Data Bank. CYANOCOBALAMIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20822082.001).
  • [ISSN] 1532-0650
  • [Journal-full-title] American family physician
  • [ISO-abbreviation] Am Fam Physician
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hematinics; 0 / Iron Compounds; 0LVT1QZ0BA / Homocysteine; 8LL8S712J7 / Methylmalonic Acid; 9007-73-2 / Ferritins; 935E97BOY8 / Folic Acid; P6YC3EG204 / Vitamin B 12
  •  go-up   go-down


47. Passioura T, Shen S, Symonds G, Dolnikov A: A retroviral library genetic screen identifies IRF-2 as an inhibitor of N-ras-induced growth suppression in leukemic cells. Oncogene; 2005 Nov 10;24(49):7327-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Activating mutations of the N-ras gene occur at relatively high frequency in acute myeloid leukemia and myelodysplastic syndrome.
  • Somewhat paradoxically, ectopic expression of activated N-ras in primary hematopoietic cells and myeloid cell lines (in some cases) can lead to inhibition of proliferation.
  • Expression of mutant N-ras in murine hematopoietic stem/progenitor cells is sufficient to induce myeloid malignancies, but these pathologies occur with long latency.
  • In the present work, the growth suppression induced by a mutant N-ras gene in U937 myeloid cells was used as the basis to screen a retroviral cDNA library for genes that prevent mutant N-ras-induced growth suppression (i.e., putative cooperating oncogenes).
  • Overexpression of this truncated PP2135 gene in U937 cells did not appear to abrogate mutant N-ras-induced growth suppression, but rather appeared to confer an increased sensitivity of U937 cells to retroviral infection, accounting for the recovery of this gene from the genetic screen.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16007130.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / IRF2 protein, human; 0 / Interferon Regulatory Factor-2
  •  go-up   go-down


48. Jung J, Kang H, Cho YS, Oh JH, Ryu MH, Chung HW, Seo JS, Lee JE, Oh B, Bhak J, Kim HL: Gene flow between the Korean peninsula and its neighboring countries. PLoS One; 2010;5(7):e11855
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The RH- and LD-free multi-dimensional scaling (MDS) method showed a broad picture of human migration from Africa to North-East Asia on our genome map, supporting results from previous haploid DNA studies.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] PLoS Genet. 2006 Dec;2(12):e190 [17194218.001]
  • [Cites] Mol Biol Evol. 2007 Aug;24(8):1596-9 [17488738.001]
  • [Cites] PLoS One. 2008;3(10):e3519 [18949038.001]
  • [Cites] Science. 2009 Dec 11;326(5959):1541-5 [20007900.001]
  • [Cites] Genetics. 2000 Jun;155(2):945-59 [10835412.001]
  • [Cites] Bioinformatics. 2000 Jul;16(7):660-1 [11038340.001]
  • [Cites] Am J Hum Genet. 2002 Jan;70(1):192-206 [11731934.001]
  • [Cites] Nat Biotechnol. 2003 Oct;21(10):1233-7 [12960966.001]
  • [Cites] Hum Genet. 2003 Dec;114(1):27-35 [14505036.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 27;101(30):11030-5 [15258291.001]
  • [Cites] Genetics. 1992 Jun;131(2):479-91 [1644282.001]
  • [Cites] Genet Epidemiol. 1993;10(6):477-82 [8314047.001]
  • [Cites] Nature. 1994 Mar 31;368(6470):455-7 [7510853.001]
  • [Cites] Am J Hum Genet. 1997 Sep;61(3):705-18 [9326336.001]
  • [Cites] Hum Hered. 1999 Jun;49(3):159-68 [10364681.001]
  • [Cites] Nature. 2005 Mar 17;434(7031):325-37 [15772651.001]
  • [Cites] Bioinformatics. 2005 May 1;21(9):1958-63 [15657097.001]
  • [Cites] Hum Genet. 2005 Oct;117(6):511-9 [16028061.001]
  • [Cites] Nature. 2005 Oct 27;437(7063):1299-320 [16255080.001]
  • [Cites] Bioinformatics. 2006 Jan 1;22(1):7-12 [16267090.001]
  • [Cites] Genetics. 2006 Apr;172(4):2431-9 [16489223.001]
  • [Cites] PLoS Genet. 2007 Nov;3(11):e185 [18039031.001]
  • (PMID = 20686617.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2912326
  •  go-up   go-down


49. Stumpf JL: Deferasirox. Am J Health Syst Pharm; 2007 Mar 15;64(6):606-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The pharmacology, clinical efficacy, adverse effects and toxicities, and the economic issues that should be considered in using deferasirox are reviewed.
  • Although survival rates improve with adequate chelation, an estimated one third to one half of patients are not compliant with deferoxamine therapy, largely because of the discomfort and demanding nature of the regimen.
  • Deferasirox has been studied in >700 adult and pediatric patients who had transfusion-related iron overload and underlying thalassemia, sickle cell anemia, myelodysplastic syndrome, Diamond-Blackfan syndrome, or another rare anemia.
  • The largest clinical study to date demonstrated the noninferiority of deferasirox 20 or 30 mg/kg/day compared with subcutaneous infusions of deferoxamine >/=35 mg/kg/day administered five days weekly in a subgroup of patients with higher hepatic iron burdens.
  • Deferasirox has been well tolerated in clinical trials.

  • Hazardous Substances Data Bank. DESFERRIOXAMINE .
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17353569.001).
  • [ISSN] 1079-2082
  • [Journal-full-title] American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • [ISO-abbreviation] Am J Health Syst Pharm
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzoates; 0 / Iron Chelating Agents; 0 / Siderophores; 0 / Triazoles; E1UOL152H7 / Iron; J06Y7MXW4D / Deferoxamine; V8G4MOF2V9 / deferasirox
  • [Number-of-references] 44
  •  go-up   go-down


50. Latagliata R, Bongarzoni V, Carmosino I, Mengarelli A, Breccia M, Borza PA, D'Andrea M, D'Elia GM, Mecarocci S, Morano SG, Petti MC, Mandelli F, Alimena G: Acute myelogenous leukemia in elderly patients not eligible for intensive chemotherapy: the dark side of the moon. Ann Oncol; 2006 Feb;17(2):281-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myelogenous leukemia in elderly patients not eligible for intensive chemotherapy: the dark side of the moon.
  • BACKGROUND: Acute Myelogenous Leukemia (AML) is a common disease in people aged>60 years.
  • About 50% of the patients are not eligible for aggressive chemotherapy (CT) and are only managed with conservative approaches.
  • Results in this subset of patients have not been reported so far.
  • PATIENTS AND METHODS: We retrospectively evaluated 244 consecutive elderly AML patients (M/F 143/101, median age 72 years, range 60-90) diagnosed at our institution from January 1989 to December 1998 and not eligible for intensive CT.
  • Eighty-nine patients (36.5%) had evolved from previous myelodysplasia (sAML).
  • Fifty-three out of 192 (26.4%) patients with available bone marrow (BM) analysis had oligoblastic leukaemia (blasts<40% and WBC<15x10(9)/l).
  • One hundred seventy-seven patients (72.5%), in order to control disease, received conservative CT, consisting of Hydroxyurea (HU) (127 patients, 71.7%), Cytarabine and 6-Thioguanine (39 patients, 22%) or low-dose cytarabine (11 patients, 6.3%).
  • CONCLUSIONS: Our data outline the great heterogeneity of elderly AML patients not eligible for intensive CT.
  • A simple scoring system including easily evaluable parameters, which could distinguish subjects with different prognosis, is proposed.


51. van de Loosdrecht AA, Westers TM, Ossenkoppele GJ: Flowcytometry in myelodysplastic syndromes: towards a new paradigm in diagnosis and prognostication? Leuk Res; 2008 Feb;32(2):205-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flowcytometry in myelodysplastic syndromes: towards a new paradigm in diagnosis and prognostication?
  • [MeSH-major] Flow Cytometry. Medical Oncology / standards. Myelodysplastic Syndromes / classification. Myelodysplastic Syndromes / diagnosis

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Leuk Res. 2008 Feb;32(2):211-3 [17675154.001]
  • (PMID = 17714781.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Comment; Editorial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


52. Wodchis WP, Naglie G, Teare GF: Validating diagnostic information on the Minimum Data Set in Ontario Hospital-based long-term care. Med Care; 2008 Aug;46(8):882-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Over 20 countries currently use the Minimum Data Set Resident Assessment Instrument (MDS) in long-term care settings for care planning, policy, and research purposes.
  • A full assessment of the quality of the diagnostic information recorded on the MDS is lacking.
  • OBJECTIVE: The primary goal of this study was to examine the quality of diagnostic coding on the MDS.
  • After linkage, each resident had 2 sources of diagnostic information: the acute discharge abstract database and the MDS.
  • Using the discharge abstract database as the reference standard, we calculated the sensitivity for each of 43 MDS diagnoses.
  • RESULTS: Compared with primary diagnoses coded in acute care abstracts, 12 of 43 MDS diagnoses attained a sensitivity of at least 0.80, including 7 of the 10 diagnoses with the highest prevalence as an acute care primary diagnosis before CCC admission.
  • CONCLUSIONS: Although the sensitivity was high for many of the most prevalent conditions, important diagnostic information is missed increasing the potential for suboptimal clinical care.
  • Researchers should exercise caution when using MDS diagnoses to identify patient populations, particularly those shown to have low sensitivity in this study.
  • [MeSH-major] Diagnosis-Related Groups / classification. Long-Term Care / statistics & numerical data. Nursing Homes / statistics & numerical data. Quality of Health Care

  • MedlinePlus Health Information. consumer health - Nursing Homes.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18665069.001).
  • [ISSN] 1537-1948
  • [Journal-full-title] Medical care
  • [ISO-abbreviation] Med Care
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


53. Chen YB, Ballen KK: Hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. F1000 Med Rep; 2009;1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematopoietic stem cell transplantation in patients with myelodysplastic syndrome.
  • Hematopoietic stem cell transplantation (HSCT) is the only curative therapy for patients with myelodysplastic syndrome (MDS).
  • Recent advances, including better prognostic algorithms, the introduction of reduced intensity conditioning regimens, and experience with alternative donors, have made HSCT a realistic option for an increasing number of patients with MDS.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1997 Mar 15;89(6):2079-88 [9058730.001]
  • [Cites] Blood. 2002 Mar 15;99(6):1943-51 [11877264.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2429-40 [12011120.001]
  • [Cites] Biol Blood Marrow Transplant. 2003 Dec;9(12):753-9 [14677114.001]
  • [Cites] Blood. 2004 Jul 15;104(2):579-85 [15039286.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1616-23 [15059843.001]
  • [Cites] Br J Haematol. 1982 Jun;51(2):189-99 [6952920.001]
  • [Cites] Br J Haematol. 1994 Aug;87(4):743-5 [7986716.001]
  • [Cites] Br J Haematol. 1996 Apr;93(1):59-67 [8611476.001]
  • [Cites] N Engl J Med. 2005 Feb 10;352(6):549-57 [15703420.001]
  • [Cites] Leukemia. 2006 Feb;20(2):322-8 [16307018.001]
  • [Cites] Bone Marrow Transplant. 2006 Feb;37(4):339-44 [16415898.001]
  • [Cites] Leukemia. 2006 Jan;20(1):128-35 [16270037.001]
  • [Cites] Blood. 2006 Aug 1;108(3):836-46 [16597592.001]
  • [Cites] N Engl J Med. 2006 Oct 5;355(14):1456-65 [17021321.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Oct;12(10):1047-55 [17067911.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Jan;13(1):82-9 [17222756.001]
  • [Cites] Cancer. 2007 Apr 15;109(8):1536-42 [17345612.001]
  • [Cites] Blood. 2008 Jan 1;111(1):86-93 [17893227.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):956-62 [10694544.001]
  • [Cites] Br J Haematol. 2001 Aug;114(2):349-57 [11529854.001]
  • [Cites] Blood. 2005 Feb 1;105(3):1343-7 [15466923.001]
  • (PMID = 20948771.001).
  • [ISSN] 1757-5931
  • [Journal-full-title] F1000 medicine reports
  • [ISO-abbreviation] F1000 Med Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2920696
  •  go-up   go-down


54. Hollenbach PW, Nguyen AN, Brady H, Williams M, Ning Y, Richard N, Krushel L, Aukerman SL, Heise C, MacBeth KJ: A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One; 2010;5(2):e9001
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines.
  • BACKGROUND: The cytidine nucleoside analogs azacitidine (AZA) and decitabine (DAC) are used for the treatment of patients with myelodysplastic syndromes and acute myeloid leukemia (AML).
  • Few non-clinical studies have directly compared the mechanisms of action of these agents in a head-to-head fashion, and the agents are often viewed as mechanistically similar DNA hypomethylating agents.
  • [MeSH-minor] Acute Disease. Antimetabolites, Antineoplastic / pharmacology. Blotting, Western. Cell Line. Cell Line, Tumor. Cell Survival / drug effects. DNA Damage. DNA Methylation / drug effects. Dose-Response Relationship, Drug. Flow Cytometry. Gene Expression / drug effects. HL-60 Cells. Humans. Leukemia, Myeloid / genetics. Leukemia, Myeloid / metabolism. Leukemia, Myeloid / pathology. Oligonucleotide Array Sequence Analysis / methods. Repressor Proteins / antagonists & inhibitors. Repressor Proteins / genetics. Repressor Proteins / metabolism

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2429-40 [12011120.001]
  • [Cites] J Clin Oncol. 2011 May 20;29(15):1987-96 [21483003.001]
  • [Cites] Cancer Res. 1970 Nov;30(11):2760-9 [5487063.001]
  • [Cites] Nat New Biol. 1971 Aug;232(33):206-11 [5285753.001]
  • [Cites] Biochim Biophys Acta. 1973 Oct 12;324(2):282-9 [4128150.001]
  • [Cites] Cancer Res. 1974 Nov;34(11):3003-9 [4138102.001]
  • [Cites] Oncology. 1974;30(5):405-22 [4142650.001]
  • [Cites] Biochem Pharmacol. 1978;27(11):1555-60 [567988.001]
  • [Cites] Cancer Res. 1980 Aug;40(8 Pt 1):2701-5 [6155997.001]
  • [Cites] Biochim Biophys Acta. 1982 Jun 30;697(3):286-94 [6179542.001]
  • [Cites] Cancer Chemother Pharmacol. 1984;13(3):191-4 [6207950.001]
  • [Cites] Leuk Res. 1984;8(6):1043-9 [6083417.001]
  • [Cites] Cancer Treat Rep. 1987 Oct;71(10):959-64 [2443243.001]
  • [Cites] Cancer Res. 1993 Jul 1;53(13):3186-92 [8319228.001]
  • [Cites] Cancer Res. 1995 Jul 15;55(14):3093-8 [7541710.001]
  • [Cites] Int J Cancer. 2005 May 1;114(5):683-95 [15609309.001]
  • [Cites] J Clin Pharmacol. 2005 May;45(5):597-602 [15831784.001]
  • [Cites] Mol Cell Biol. 2005 Jun;25(11):4727-41 [15899874.001]
  • [Cites] Nat Rev Drug Discov. 2006 Jan;5(1):37-50 [16485345.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2794-800 [16510601.001]
  • [Cites] Cancer. 2006 Apr 15;106(8):1794-803 [16532500.001]
  • [Cites] Leuk Res. 2007 Apr;31(4):497-506 [17056112.001]
  • [Cites] Mol Cancer Ther. 2007 Jun;6(6):1718-27 [17575103.001]
  • [Cites] Clin Cancer Res. 2007 Jul 15;13(14):4225-32 [17634552.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3884-91 [17679729.001]
  • [Cites] Mol Cell Biol. 2008 Jan;28(2):752-71 [17991895.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Apr;61(5):759-66 [17564707.001]
  • [Cites] Leuk Lymphoma. 2008 Apr;49(4):650-1 [18398728.001]
  • [Cites] Haematologica. 2008 Jun;93(6):860-9 [18443271.001]
  • [Cites] Oncogene. 2008 Jun 5;27(25):3615-23 [18223691.001]
  • [Cites] Mol Cancer Ther. 2008 Sep;7(9):2998-3005 [18790780.001]
  • [Cites] Blood. 2009 Jan 15;113(3):659-67 [18931345.001]
  • [Cites] Lancet Oncol. 2009 Mar;10(3):223-32 [19230772.001]
  • [Cites] Leukemia. 2009 Jun;23(6):1019-28 [19194470.001]
  • [Cites] Expert Rev Anticancer Ther. 2009 Jul;9(7):875-84 [19589026.001]
  • [Cites] Leuk Res. 2003 Nov;27(11):999-1007 [12859993.001]
  • (PMID = 20126405.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / DMAP1 protein, human; 0 / Repressor Proteins; 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
  • [Other-IDs] NLM/ PMC2814859
  •  go-up   go-down


55. Miano M, Labopin M, Hartmann O, Angelucci E, Cornish J, Gluckman E, Locatelli F, Fischer A, Egeler RM, Or R, Peters C, Ortega J, Veys P, Bordigoni P, Iori AP, Niethammer D, Rocha V, Dini G, Paediatric Diseases Working Party of the European Group for Blood and Marrow Transplantation: Haematopoietic stem cell transplantation trends in children over the last three decades: a survey by the paediatric diseases working party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant; 2007 Jan;39(2):89-99
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The number of allogeneic HSCTs (allo-HSCTs) for acute lymphoblastic leukaemia, acute myeloblastic leukaemia and chronic myeloid leukaemia remained stable, whereas it increased for myelodysplastic syndromes and lymphomas, and decreased significantly for non-malignant diseases (P<0.0001).
  • The number of autologus HSCTs (auto-HSCTs) for acute leukaemia decreased significantly, whereas it increased for solid tumours (P<0.0001).
  • [MeSH-minor] Blood Transfusion / statistics & numerical data. Bone Marrow Transplantation / statistics & numerical data. Child. Data Collection. Europe. Humans. Leukemia / therapy. Registries. Transplantation, Autologous. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17213848.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


56. Hamdi W, Ogawara H, Handa H, Tsukamoto N, Murakami H: Clinical significance of Th1/Th2 ratio in patients with myelodysplastic syndrome. Int J Lab Hematol; 2009 Dec;31(6):630-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of Th1/Th2 ratio in patients with myelodysplastic syndrome.
  • In this study, we attempted to evaluate the clinical significance of T helper 1 (Th1)/T helper 2 (Th2) ratio in patients with myelodysplastic syndrome (MDS), five refractory anaemia (RA), four refractory anaemia with ringed sideroblasts (RARS), 31 refractory cytopenia with multilineage dysplasia (RCMD), nine refractory anaemia with excess blast-1 (RAEB-1) and seven refractory anaemia with excess blast-2 (RAEB-2).
  • Mean Th1/Th2 ratios in each MDS group were as follows: RA/RARS, 8.8 (95% CI, 5.8-11.8), RCMD, 14.7 (95% CI, 9.5-19.9), RAEB-1, 10.6 (95% CI, 4.6-16.6), RAEB-2, 12.8 (95% CI, 3.0-22.7) and control 12.8 (95% CI, 9.6-16.1).
  • [MeSH-major] Myelodysplastic Syndromes / immunology. Th1 Cells / immunology. Th2 Cells / immunology


57. Fry NK, Duncan J, Edwards MT, Tilley RE, Chitnavis D, Harman R, Hammerton H, Dainton L: A UK clinical isolate of Bordetella hinzii from a patient with myelodysplastic syndrome. J Med Microbiol; 2007 Dec;56(Pt 12):1700-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A UK clinical isolate of Bordetella hinzii from a patient with myelodysplastic syndrome.
  • What is believed to be the first clinical isolate of Bordetella hinzii in the UK, from a patient with myelodysplastic syndrome, is described.
  • It appears that the underlying immune deficiency of the patient increased the susceptibility to opportunistic infection with this organism.
  • [MeSH-major] Bordetella / isolation & purification. Bordetella Infections / microbiology. Myelodysplastic Syndromes / microbiology. Opportunistic Infections / microbiology


58. Mariscal-Arcas M, Rivas A, Monteagudo C, Granada A, Cerrillo I, Olea-Serrano F: Proposal of a Mediterranean diet index for pregnant women. Br J Nutr; 2009 Sep;102(5):744-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to propose a diet quality index for pregnancy based on a Mediterranean-type diet (MDS-P), evaluating the diet of a group of pregnant women by applying the Mediterranean Diet Score (MDS) and evaluating their intake of micronutrients required in optimal amounts during pregnancy, such as Fe, folic acid and Ca.
  • The data used to construct this index (MDS-P) were gathered by means of a FFQ specifically designed for pregnant women.
  • The mean MDS of this group, was 4.31 (sd 1.32), considered to represent satisfactory compliance with the Mediterranean diet (range 0-8).
  • The mean MDS-P (range 0-11), which also takes account of dietary intake or supplements of folic acid, Fe and Ca was 7.53 (sd 1.44), indicating a compliance of around 70 %.
  • The present study findings suggest that the MDS-P, which evaluates the adequacy of folic acid, Fe and Ca as well as compliance with the Mediterranean diet, may represent a valid tool for the specific assessment of the diet of pregnant women living in countries in the Mediterranean area.

  • Hazardous Substances Data Bank. FOLIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19243664.001).
  • [ISSN] 1475-2662
  • [Journal-full-title] The British journal of nutrition
  • [ISO-abbreviation] Br. J. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Micronutrients; 935E97BOY8 / Folic Acid
  •  go-up   go-down


59. Finke J, Nagler A: Viewpoint: What is the role of allogeneic haematopoietic cell transplantation in the era of reduced-intensity conditioning--is there still an upper age limit? A focus on myeloid neoplasia. Leukemia; 2007 Jul;21(7):1357-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Viewpoint: What is the role of allogeneic haematopoietic cell transplantation in the era of reduced-intensity conditioning--is there still an upper age limit? A focus on myeloid neoplasia.
  • Allogeneic haematopoietic cell transplantation (HCT) is the most effective curative therapy in acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS).
  • Incidence of AML and MDS increases with age, peaking in the seventh decade.
  • The success of RIC HCT relies on the alloreactivity of the donor immune system and the graft-versus-leukaemia effect.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Age Factors. Aged. Humans. Middle Aged. Myelodysplastic Syndromes / therapy. Transplantation Immunology. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17508002.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 45
  •  go-up   go-down


60. Gupta V, Tallman MS, He W, Logan BR, Copelan E, Gale RP, Khoury HJ, Klumpp T, Koreth J, Lazarus HM, Marks DI, Martino R, Rizzieri DA, Rowe JM, Sabloff M, Waller EK, DiPersio JF, Bunjes DW, Weisdorf DJ: Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. Blood; 2010 Sep 16;116(11):1839-48
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis.
  • We compared the outcomes of unrelated donor (URD, n = 358) with human leukocyte antigen (HLA)-matched sibling donor (MSD, n = 226) transplantations in patients with acute myeloid leukemia (AML) in first complete remission (CR1) having unfavorable cytogenetics at diagnosis.
  • Three-year leukemia-free survival (LFS) for MSD was 42% (95% confidence interval [CI], 35%-48%) compared with 34% (95% CI, 28%-41%) for HLA-well-matched URD and 29% (95% CI, 20%-39%) for partially-matched URD (P = .08).
  • LFS and OS were significantly inferior for HLA-partially-matched URD recipients, those with prior myelodysplastic syndrome, and those older than 50 years.
  • Patients with chronic graft-versus-host disease had a significantly lower risk of relapse (RR = 0.68, 95% CI, 0.47-0.99, P = .05).

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5207-15 [17114653.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1712-6 [16239431.001]
  • [Cites] Bone Marrow Transplant. 2010 Feb;45(2):219-34 [19584824.001]
  • [Cites] Blood. 2002 Mar 15;99(6):1971-7 [11877268.001]
  • [Cites] Biol Blood Marrow Transplant. 2003 Apr;9(4):215-33 [12720215.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1232-40 [12714526.001]
  • [Cites] J Clin Oncol. 2004 Feb 1;22(3):416-23 [14691124.001]
  • [Cites] Blood. 2004 Oct 1;104(7):1923-30 [15191952.001]
  • [Cites] Bone Marrow Transplant. 1995 Jun;15(6):825-8 [7581076.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1767-77 [9164184.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3515-20 [9808542.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1652-8 [15742336.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:384-9 [16304408.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):444-53 [16344316.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4075-83 [11110676.001]
  • [Cites] Br J Haematol. 2006 Nov;135(4):450-74 [17054678.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5695-702 [17116940.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 May;13(5):601-7 [17448920.001]
  • [Cites] Blood. 2007 May 1;109(9):3658-66 [17213292.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4576-83 [17785583.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Feb;14(2):135-6 [18215776.001]
  • [Cites] Bone Marrow Transplant. 2008 Mar;41(5):425-37 [18209727.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jul;14(7):748-58 [18541193.001]
  • [Cites] J Clin Oncol. 2008 Oct 10;26(29):4791-7 [18695255.001]
  • [Cites] J Clin Oncol. 2008 Nov 10;26(32):5183-91 [18768435.001]
  • [Cites] Blood. 2009 Mar 26;113(13):3110-8 [19059878.001]
  • [Cites] Leukemia. 2009 Apr;23(4):635-40 [19151786.001]
  • [Cites] JAMA. 2009 Jun 10;301(22):2349-61 [19509382.001]
  • [Cites] Blood. 2010 Jan 21;115(3):453-74 [19880497.001]
  • [CommentIn] Blood. 2010 Sep 16;116(11):1822-3 [20847206.001]
  • (PMID = 20538804.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / U01 HL069294; United States / NCI NIH HHS / CA / U24 CA076518; United States / NHLBI NIH HHS / HL / 5U01HL069294; United States / NCI NIH HHS / CA / U24 CA76518
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA Antigens
  • [Other-IDs] NLM/ PMC3173984
  •  go-up   go-down


61. Prybis BG, Pugh L, Stasikelis PJ: Cardiac screening in congenital spine disorders. J Pediatr Orthop; 2007 Mar;27(2):123-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Children with congenital spine disorders are known to have a high prevalence of congenital heart disease.
  • It was our hypothesis that the anomalies are clinically obvious; thus, screening with electrocardiogram (ECG) or echocardiogram for occult disease would prove unnecessary after orthopaedic referral.
  • METHODS: The records and radiographs of 190 consecutive children known to have a congenital vertebral abnormality (excluding myelodysplasia and sacral agenesis) were retrospectively reviewed.
  • RESULTS: Twenty-four children presented to the orthopaedist with an established diagnosis of congenital heart disease.
  • None of the 27 children screened with ECG and pediatric or cardiology consultation, and none of the 75 who underwent evaluation only by the orthopaedist were detected to have a cardiac abnormality.
  • CONCLUSIONS: The presentation of congenital heart disease associated with congenital spine disorders is general clinically evident and made before the referral to the orthopaedist.
  • Routine referral by the orthopaedist for ECG or echocardiogram is not supported by this work.
  • [MeSH-major] Heart Defects, Congenital / complications. Heart Defects, Congenital / diagnosis. Spinal Curvatures / complications. Spinal Curvatures / congenital

  • MedlinePlus Health Information. consumer health - Congenital Heart Defects.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17314633.001).
  • [ISSN] 0271-6798
  • [Journal-full-title] Journal of pediatric orthopedics
  • [ISO-abbreviation] J Pediatr Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Stauder R, Nösslinger T, Pfeilstöcker M, Sperr WR, Wimazal F, Krieger O, Valent P: Impact of age and comorbidity in myelodysplastic syndromes. J Natl Compr Canc Netw; 2008 Oct;6(9):927-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of age and comorbidity in myelodysplastic syndromes.
  • Myelodysplastic syndromes (MDS) represent a heterogeneous group of myeloid neoplasms that are preferentially diagnosed in the elderly.
  • With the increase in older patients with MDS in the Western world and the availability of more therapeutic options, new strategies and algorithms for optimal management and treatment of these patients must be developed.
  • Although age is recognized as an important adverse variable affecting survival, most scoring systems have not included age in score risk calculations.
  • Comorbidity is of particular importance and a frequent covariable in elderly patients with MDS.
  • Advanced age should not exclude a patient with MDS from appropriate treatment, and age alone should not be considered a surrogate marker for functional decline or comorbidities.
  • This article discusses the need to improve scoring systems, individualized risk-assessment, and treatment algorithms for elderly patients with MDS by including age and comorbidities.
  • [MeSH-major] Myelodysplastic Syndromes / epidemiology


63. Bimler D, Kirkland J: Constructing personality maps, mapping personality constructs: multidimensional scaling recovers the big five factors from internal and external structure. Span J Psychol; 2007 May;10(1):68-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Similarity data of both kinds were analyzed with multidimensional scaling (MDS) to provide a parsimonious representation of underlying structure.
  • Canonical correlation was employed to find the number of dimensions shared across MDS solutions.
  • Interpretation of the results was facilitated by individual-differences MDS, which can select an optimal set of underlying dimensions, and at the same time accommodate the differences between data sets that arise when data-collection procedures differ in the relative emphasis they place upon those dimensions.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17549879.001).
  • [ISSN] 1138-7416
  • [Journal-full-title] The Spanish journal of psychology
  • [ISO-abbreviation] Span J Psychol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


64. Fries BE, Wodchis WP, Blaum C, Buttar A, Drabek J, Morris JN: A national study showed that diagnoses varied by age group in nursing home residents under age 65. J Clin Epidemiol; 2005 Feb;58(2):198-205
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study uses data gathered from the Resident Assessment Instrument's Minimum Data Set (MDS) to describe these relatively rare residents.
  • STUDY DESIGN AND SETTING: The study uses MDS assessments of close to three-quarter million residents in nine states from 1994 to 1996.
  • The prevalence of residents with unique conditions may suggest the need to modify the MDS assessment instrument.
  • [MeSH-major] Disabled Persons. Mental Disorders / epidemiology. Nervous System Diseases / epidemiology. Nursing Homes


65. Forget BG: De novo and acquired forms of alpha thalassemia. Curr Hematol Rep; 2006 Mar;5(1):11-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] De novo and acquired forms of alpha thalassemia.
  • Alpha thalassemia is a genetic disorder of hemoglobin production that typically is inherited in an autosomal co-dominant fashion.
  • Rare forms of alpha-thalassemia, however, occur as de novo or acquired disorders.
  • These disorders occur in two clinical situations:.
  • 1) alpha-thalassemia associated with mental retardation, and 2) acquired alpha-thalassemia (HbH disease) associated with myelodysplastic syndrome.
  • [MeSH-minor] Gene Expression Regulation. Globins / genetics. Humans. Intellectual Disability / etiology. Intellectual Disability / genetics. Myelodysplastic Syndromes / etiology. Myelodysplastic Syndromes / genetics. Syndrome

  • Genetic Alliance. consumer health - Alpha-Thalassemia.
  • Genetic Alliance. consumer health - Thalassemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16537041.001).
  • [ISSN] 1541-0714
  • [Journal-full-title] Current hematology reports
  • [ISO-abbreviation] Curr. Hematol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nuclear Proteins; 9004-22-2 / Globins; EC 3.6.4.- / DNA Helicases; EC 3.6.4.12 / ATRX protein, human
  • [Number-of-references] 11
  •  go-up   go-down


66. Travaglino E, Comincini S, Benatti C, Azzalin A, Nano R, Rosti V, Ferretti L, Invernizzi R: Overexpression of the Doppel protein in acute myeloid leukaemias and myelodysplastic syndromes. Br J Haematol; 2005 Mar;128(6):877-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of the Doppel protein in acute myeloid leukaemias and myelodysplastic syndromes.
  • We investigated the expression patterns and distribution of Doppel (Dpl), the product of the prion-like gene PRND, in the leukaemic cell lines HL-60 and K562 and in bone marrow cells from 44 patients with acute myeloid leukaemia (AML) and 63 patients with myelodysplastic syndrome (MDS).
  • Whereas normal samples were negative or showed very weak expression that was restricted to CD34(+) cells, Dpl was detected in both cell lines and in most AML and MDS cases by immunocytochemistry and Western blotting.
  • Quantitative reverse transcription polymerase chain reaction revealed variable mRNA levels in almost all AML and MDS cases, but barely detectable levels in normal bone marrow.
  • PRND expression was higher in advanced compared with early MDS (P = 0.01), but Dpl levels did not predict disease progression.
  • In AML there was no correlation between Dpl levels and clinical or laboratory findings.
  • The molecular mechanism of the observed overexpression is unknown; however, the differential Dpl distribution in AML and MDS versus healthy subjects makes it a possible leukaemia-associated antigen that could be useful for diagnostic and therapeutic purposes.
  • [MeSH-major] Leukemia, Myeloid / metabolism. Myelodysplastic Syndromes / metabolism. Prions / metabolism
  • [MeSH-minor] Acute Disease. Aged. Antigens, CD34 / metabolism. Blotting, Western. Female. GPI-Linked Proteins. HL-60 Cells. Humans. Immunohistochemistry. Male. Middle Aged. Polymerase Chain Reaction / methods. RNA, Messenger / metabolism


67. Pawarode A, Finlay E, Sait SN, Barcos M, Baer MR: Isochromosome 1q in a myelodysplastic syndrome after treatment for acute promyelocytic leukemia. Cancer Genet Cytogenet; 2006 Jun;167(2):155-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isochromosome 1q in a myelodysplastic syndrome after treatment for acute promyelocytic leukemia.
  • A growing body of literature reports therapy-related myelodysplastic syndrome (t-MDS) and acute myeloid leukemia (t-AML) in patients treated successfully for acute promyelocytic leukemia (APL).
  • We report a t-MDS with an isochromosome 1q as a sole abnormality, 47,XY,+1,i(1)(q10), in a 46-year-old man with APL 14 years after he was treated with cytosine arabinosine and daunorubicin.
  • The literature on t-MDS/t-AML after APL therapy and on isochromosome 1q is reviewed.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Chromosomes, Human, Pair 1. Cytarabine / adverse effects. Daunorubicin / adverse effects. Isochromosomes. Leukemia, Promyelocytic, Acute / drug therapy. Myelodysplastic Syndromes / genetics


68. Issa JP, Kantarjian H: Azacitidine. Nat Rev Drug Discov; 2005 05;Suppl:S6-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Azacitidine (Vidaza; Pharmion), an inhibitor of DNA methylation, was approved by the US FDA for the treatment of myelodysplastic syndromes in May 2004.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Azacitidine / therapeutic use. Myelodysplastic Syndromes / drug therapy
  • [MeSH-minor] Clinical Trials as Topic. DNA Methylation / drug effects. Humans. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • SciCrunch. DrugBank: Data: Chemical .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15962522.001).
  • [ISSN] 1474-1776
  • [Journal-full-title] Nature reviews. Drug discovery
  • [ISO-abbreviation] Nat Rev Drug Discov
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; M801H13NRU / Azacitidine
  • [Number-of-references] 17
  •  go-up   go-down


69. Hussein K, von Neuhoff N, Büsche G, Buhr T, Kreipe H, Bock O: Opposite expression pattern of Src kinase Lyn in acute and chronic haematological malignancies. Ann Hematol; 2009 Nov;88(11):1059-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By contrast, Lyn deficiency was shown to be responsible for a phenotype resembling myeloproliferative neoplasm (MPN) in mice.
  • We aimed to shed more light on Lyn's role in haematological neoplasm and systematically investigated Lyn expression in MPN, acute and chronic leukaemia subtypes (n = 236).
  • On top, B-cell chronic lymphocytic leukaemia (B-CLL) and chronic myeloid leukaemia significantly overexpressed Lyn when compared to de novo acute lymphoblastic leukaemia, de novo acute myeloid leukaemia (AML) and Philadelphia-chromosome-negative myeloproliferative neoplasms (p < 0.001).
  • Most of acute leukaemia subtypes showed a notable down-regulation of Lyn mRNA but anyhow individual cases were labelled for the active form of Lyn protein.
  • Intriguingly, secondary AML evolved in myelodysplastic syndromes revealed almost undetectable Lyn.
  • We conclude that tyrosine kinase Lyn contributes to the malignant phenotype in certain leukaemia subtypes and therefore attracts targeted therapy.
  • [MeSH-major] Leukemia / enzymology. Neoplasm Proteins / biosynthesis. src-Family Kinases / biosynthesis
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. Bone Marrow / enzymology. Bone Marrow / pathology. Child. Child, Preschool. Chronic Disease. Female. Gene Expression Regulation, Leukemic. Humans. Janus Kinase 2 / genetics. Male. MicroRNAs / biosynthesis. MicroRNAs / genetics. Middle Aged. Neoplasms, Second Primary / enzymology. Neoplasms, Second Primary / genetics. RNA, Messenger / biosynthesis. RNA, Neoplasm / biosynthesis. Receptors, Thrombopoietin / genetics. Young Adult

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19290526.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / Mirn337 microRNA, human; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Receptors, Thrombopoietin; 143641-95-6 / MPL protein, human; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2; EC 2.7.10.2 / lyn protein-tyrosine kinase; EC 2.7.10.2 / src-Family Kinases
  •  go-up   go-down


70. Gilkey D, Caddy L, Keefe T, Wahl G, Mobus R, Enebo B, Duvall K, Griffiths K: Colorado workers' compensation: medical vs chiropractic costs for the treatment of low back pain. J Chiropr Med; 2008 Dec;7(4):127-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cases were matched using the International Classification of Diseases, Ninth Revision, codes 722 (intervertebral disk disorders), 724 (other and unspecified disorders of the back), and 847 (sprains and strains of other and unspecified parts).
  • RESULTS: The total amount paid by the insurance company was 1.7 times higher for patients treated by doctors of chiropractic (DCs) compared with those treated by medical doctors (MDs), and the cost of clinical treatment was 3.3 times higher for the DCs than MDs.
  • CONCLUSION: The cost for treatment by DCs was greater than that of MDs for similarly classified conditions affecting the low back.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Manipulative Physiol Ther. 1989 Oct;12(5):335-44 [2532676.001]
  • [Cites] Spine (Phila Pa 1976). 1986 Apr;11(3):241-5 [2940707.001]
  • [Cites] J Manipulative Physiol Ther. 1993 Mar-Apr;16(3):161-8 [8492059.001]
  • [Cites] Spine (Phila Pa 1976). 1998 Nov 1;23(21):2329-36 [9820914.001]
  • [Cites] Bus Health. 1998 Mar;16(3):50, 52 [10177726.001]
  • [Cites] Am J Public Health. 1999 Jul;89(7):1029-35 [10394311.001]
  • [Cites] J Manipulative Physiol Ther. 2001 Jun;24(5):309-16 [11416820.001]
  • [Cites] Am J Public Health. 2002 Oct;92(10):1628-33 [12356612.001]
  • [Cites] Spine (Phila Pa 1976). 2003 Feb 1;28(3):292-7; discussion 298 [12567035.001]
  • [Cites] Milbank Q. 2003;81(1):107-38, table of contents [12669653.001]
  • [Cites] J Occup Environ Med. 2004 Nov;46(11):1166-73 [15534504.001]
  • [Cites] Spine J. 2006 May-Jun;6(3):282-8 [16651222.001]
  • [Cites] J Manipulative Physiol Ther. 1991 Mar-Apr;14(3):177-84 [1828492.001]
  • [Cites] Annu Rev Public Health. 1991;12:141-56 [1828670.001]
  • [Cites] J Occup Med. 1991 Aug;33(8):847-52 [1834819.001]
  • (PMID = 19646374.001).
  • [ISSN] 1556-3707
  • [Journal-full-title] Journal of chiropractic medicine
  • [ISO-abbreviation] J Chiropr Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2697604
  •  go-up   go-down


71. Wang R, Gross CP, Halene S, Ma X: Neighborhood socioeconomic status influences the survival of elderly patients with myelodysplastic syndromes in the United States. Cancer Causes Control; 2009 Oct;20(8):1369-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neighborhood socioeconomic status influences the survival of elderly patients with myelodysplastic syndromes in the United States.
  • The potential role of socioeconomic status (SES) in the survival of patients with myelodysplastic syndromes (MDS) has not been evaluated.
  • We conducted the first study to assess the prognostic role of neighborhood SES among a cohort of 2,118 patients (age >/= 66 years) who were diagnosed with incident MDS in the United States during 2001-2002.
  • After adjusting for age, gender, comorbidities, and histological subtypes, compared with MDS patients lived in high-SES census tracts, those resided in medium (HR = 1.14, 95% CI: 1.01-1.30) and low (HR = 1.17, 95% CI: 1.02-1.34) SES census tracts had significantly increased the risks of death.
  • In conclusion, this population-based study suggests that neighborhood SES status is a significant and independent determinant of survival among elderly patients with MDS in the United States.

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology (Williston Park). 2007 Jan;21(1):43-54; discussion 57-8, 62 [17313156.001]
  • [Cites] JAMA. 2006 Dec 13;296(22):2683-93 [17164454.001]
  • [Cites] Cancer. 2007 Apr 15;109(8):1536-42 [17345612.001]
  • [Cites] Chest. 2008 Jan;133(1):72-8 [17989164.001]
  • [Cites] Leuk Res. 2008 Mar;32(3):413-20 [17727945.001]
  • [Cites] Leuk Lymphoma. 2008 May;49(5):917-23 [18464111.001]
  • [Cites] Cancer. 2008 Aug 1;113(3):582-91 [18613122.001]
  • [Cites] Am J Epidemiol. 2008 Sep 15;168(6):611-9 [18687664.001]
  • [Cites] Eur J Cancer. 2008 Sep;44(14):2058-73 [18657412.001]
  • [Cites] Health Aff (Millwood). 2000 Jan-Feb;19(1):210-20 [10645089.001]
  • [Cites] Cancer Causes Control. 2001 Oct;12(8):703-11 [11562110.001]
  • [Cites] Br J Cancer. 2008 Sep 23;99 Suppl 1:S104-6 [18813238.001]
  • [Cites] Br J Cancer. 2008 Sep 23;99 Suppl 1:S116-8 [18813243.001]
  • [Cites] Eur J Clin Invest. 2008 Dec;38(12):945-52 [19021720.001]
  • [Cites] Cancer. 2008 Dec 1;113(11):3231-41 [18937267.001]
  • [Cites] Am J Hematol. 2009 Mar;84(3):177-86 [19195035.001]
  • [Cites] Leuk Res. 2009 Dec;33(12):1594-8 [19324411.001]
  • [Cites] J Aging Health. 2001 Aug;13(3):329-54 [11813730.001]
  • [Cites] Soc Sci Med. 2002 Jul;55(1):125-39 [12137182.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-3-18 [12187163.001]
  • [Cites] Med Care. 2004 May;42(5):482-6 [15083109.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] Epidemiol Rev. 1988;10:87-121 [3066632.001]
  • [Cites] J Clin Epidemiol. 1993 Oct;46(10):1075-9; discussion 1081-90 [8410092.001]
  • [Cites] Blood. 1997 Mar 15;89(6):2079-88 [9058730.001]
  • [Cites] Cancer Causes Control. 1998 Aug;9(4):369-80 [9794168.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 16;97(4):257-64 [15713960.001]
  • [Cites] J Health Soc Behav. 2005 Mar;46(1):15-31 [15869118.001]
  • [Cites] Ann Oncol. 2006 Jan;17(1):5-19 [16143594.001]
  • [Cites] Soc Sci Med. 2006 Mar;62(5):1291-303 [16129534.001]
  • [Cites] Exp Hematol. 2007 Apr;35(4 Suppl 1):137-43 [17379099.001]
  • (PMID = 19455395.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / 1 K08 AG24842; United States / NCI NIH HHS / CA / CA119108-03; United States / NIA NIH HHS / AG / K08 AG024842; United States / NCI NIH HHS / CA / K07 CA119108-03; United States / NCI NIH HHS / CA / K07 CA119108
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS226254; NLM/ PMC2921772
  •  go-up   go-down


72. Fujino Y, Horiuchi H, Mizukoshi F, Baba K, Goto-Koshino Y, Ohno K, Tsujimoto H: Prevalence of hematological abnormalities and detection of infected bone marrow cells in asymptomatic cats with feline immunodeficiency virus infection. Vet Microbiol; 2009 May 12;136(3-4):217-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Myeloid dysplasia was observed in 4 cats with neutropenia of which 2 cats with concurrent thrombocytopenia presented morphological abnormalities of megakaryocytes.
  • Present results suggest that FIV infection of BM cells can cause peripheral blood cytopenia and myelodysplasia even if the cat is asymptomatic.
  • [MeSH-major] Bone Marrow Cells / virology. Feline Acquired Immunodeficiency Syndrome / blood. Feline Acquired Immunodeficiency Syndrome / virology. Immunodeficiency Virus, Feline / isolation & purification

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19110384.001).
  • [ISSN] 0378-1135
  • [Journal-full-title] Veterinary microbiology
  • [ISO-abbreviation] Vet. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


73. Cang S, Lu Q, Ma Y, Liu D: Clinical advances in hypomethylating agents targeting epigenetic pathways. Curr Cancer Drug Targets; 2010 Aug;10(5):539-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical advances in hypomethylating agents targeting epigenetic pathways.
  • Two DNA methyltransferase inhibitors, azacitidine and decitabine, have been licensed for clinical therapy for patients with myelodysplastic syndrome.
  • In this review we summarize recent clinical developments on novel hypomethylating agents and new regimens from clinical trials for epigenetic therapy of cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20384584.001).
  • [ISSN] 1873-5576
  • [Journal-full-title] Current cancer drug targets
  • [ISO-abbreviation] Curr Cancer Drug Targets
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 50
  •  go-up   go-down


74. Qian W, Liu J, Jin J, Ni W, Xu W: Arsenic trioxide induces not only apoptosis but also autophagic cell death in leukemia cell lines via up-regulation of Beclin-1. Leuk Res; 2007 Mar;31(3):329-39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Arsenic trioxide induces not only apoptosis but also autophagic cell death in leukemia cell lines via up-regulation of Beclin-1.
  • Although recent data shows that arsenic trioxide (As2O3) is capable of inducing cell death via cell cycle arrest and apoptosis both in acute promyelocytic leukemia (APL) and in non-APL cells, the mechanisms of As2O3-mediated cell death are not fully understood.
  • In this study, we investigated the in vitro effects of As2O3 on cell growth inhibition and cell death in human T-lymphocytic leukemia and myelodysplastic syndrome (MDS) cell lines.
  • Autophagic cell death (programmed cell death type II) and apoptosis (programmed cell death type I) were activated together in leukemia cell lines after exposed to As2O3.
  • Finally, leukemia cells treated with 4 microM As2O3 showed a considerable up-regulation of Beclin-1 (a Bcl-2-interacting protein) expression, which was independent of transcription of mRNA and required protein synthesis.
  • In addition, Molt-4 cells treated with As2O3 exhibited the down-regulation of Bax protein expression, suggesting that Bax may be involved in accumulating of Beclin-1 and triggering autophagic cell death in As2O3-treated leukemia cells.
  • These results may lead to a better understanding of the mechanism of action of As2O3, and provide a suggestion that As2O3 may be of therapeutic value for the treatment of patients with human T-lymphocytic leukemia and myelodysplastic syndrome.
  • [MeSH-major] Apoptosis Regulatory Proteins / metabolism. Arsenicals / pharmacology. Leukemia, T-Cell / drug therapy. Membrane Proteins / metabolism. Myelodysplastic Syndromes / drug therapy. Oxides / pharmacology

  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16882451.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Arsenicals; 0 / BECN1 protein, human; 0 / Membrane Proteins; 0 / Oxides; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


75. Matsuda A: [New developments of morphologic diagnosis, classification and prognostic scoring system in myelodysplastic syndromes]. Rinsho Ketsueki; 2007 Oct;48(10):1320-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [New developments of morphologic diagnosis, classification and prognostic scoring system in myelodysplastic syndromes].
  • [MeSH-major] Myelodysplastic Syndromes / classification. Myelodysplastic Syndromes / pathology

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17933116.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 28
  •  go-up   go-down


76. Özcan MA, Pişkin Ö, Alacacıoğlu İ, Ündar B: Platelet satellitism in a pregnant woman. Turk J Haematol; 2006 Jun 5;23(2):119
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • t(1;3)(p36;p21) is a recurrent reciprocal translocation found in a subset of myelodysplastic syndrome (MDS)/acute myelogenous leukemia (AML) characterized by trilineage dysplasia, especially dysmegakaryopoiesis and poor prognosis.
  • We identified a recurring translocation, t(1;3)(p36;p21), in our patient with MDS/AML(M2), although she had not been given any kind of treatment previously.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27265295.001).
  • [ISSN] 1300-7777
  • [Journal-full-title] Turkish journal of haematology : official journal of Turkish Society of Haematology
  • [ISO-abbreviation] Turk J Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


77. Mobbs EJ: The psychological outcome of constitutional delay of growth and puberty. Horm Res; 2005;63 Suppl 1:1-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Growth studies are important because endocrinologists need to be able to give not only diagnostic but also prognostic indication to those of SS, and give advice for or against treatment.
  • From the psychological perspective, the elements of diagnosis and prognosis, attitudinal influences both social and individual, treatment, and psychological issues which could have bearing on SS are drawn together.
  • Where there is a poor psychosocial outcome finding, the MDSS patients seem to be more like those with growth hormone (GH) deficiency.

  • MedlinePlus Health Information. consumer health - Growth Disorders.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16161286.001).
  • [ISSN] 0301-0163
  • [Journal-full-title] Hormone research
  • [ISO-abbreviation] Horm. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone
  •  go-up   go-down


78. Yilmaz Z, Sahin FI, Kizilkilic E, Karakus S, Boga C, Ozdogu H: Conventional and molecular cytogenetic findings of myelodysplastic syndrome patients. Clin Exp Med; 2005 Jul;5(2):55-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conventional and molecular cytogenetic findings of myelodysplastic syndrome patients.
  • Myelodysplastic syndrome (MDS) involves myeloid cells of the bone marrow, which is important in progressive bone marrow insufficiency.
  • Of all MDS patients, 40%-50% have at least one chromosomal rearrangement.
  • Loss of specific chromosomal regions like 5q- and 7q- are usually the secondary cytogenetic abnormalities associated with MDS.
  • In order to detect chromosome abnormalities associated with MDS, bone marrow samples from 26 patients diagnosed as MDS were obtained prior to chemotherapy.
  • Twenty-one patients had normal karyotypes and four patients had abnormal karyotypes, while in one patient we could not obtain metaphases from cultures.
  • Our results show that both methods are important in diagnosis and follow up of MDS patients.
  • When used together, conventional cytogenetics and FISH detect clinically significant chromosome abnormalities in MDS patients.
  • [MeSH-major] Myelodysplastic Syndromes / genetics


79. Karp JE, Lancet JE: Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia. Biologics; 2008 Sep;2(3):491-500
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia.
  • Tipifarnib is an orally bioavailable, nonpeptidomimetic methylquinolone FTI that has exhibited clinical activity in patients with myeloid malignancies including elderly adults with acute myelogenous leukemia (AML) who are not candidates for traditional cytotoxic chemotherapy, patients with high-risk myelodysplasia, myeloproliferative disorders, and imatinib-resistant chronic myelogenous leukemia.
  • Because of its relatively low toxicity profile, tipifarnib provides an important alternative to traditional cytotoxic approaches for elderly patients who are not likely to tolerate or even benefit from aggressive chemotherapy.
  • In this review, we will focus on the clinical development of tipifarnib for treatment of newly diagnosed AML, both as induction therapy for elderly adults with poor-risk AML and as maintenance therapy following achievement of first complete remission following induction and consolidation therapies for poor-risk AML.
  • The clinical and correlative laboratory trials in progress and under development will provide the critical foundations for defining the optimal roles of tipifarnib and in patients with AMl and other hematologic malignancies.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2003 Aug 29;278(35):32493-6 [12842888.001]
  • [Cites] Am J Clin Pathol. 2003 May;119(5):672-80 [12760285.001]
  • [Cites] Haematologica. 2003 Feb;88(2):229-30 [12604418.001]
  • [Cites] Blood. 2001 Sep 1;98(5):1302-11 [11520775.001]
  • [Cites] Blood. 2001 Aug 1;98(3):548-53 [11468148.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3361-9 [11369625.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2254-60 [17404110.001]
  • [Cites] Leukemia. 2007 Apr;21(4):739-46 [17268526.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1387-94 [17082323.001]
  • [Cites] Blood. 2007 Jan 15;109(2):431-48 [16960150.001]
  • [Cites] Nature. 2006 Oct 12;443(7112):713-6 [16964241.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1677-83 [16670265.001]
  • [Cites] Curr Treat Options Oncol. 2006 Jul;7(4):285-94 [16916489.001]
  • [Cites] Blood. 2006 Jul 15;108(2):685-96 [16597596.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2480-9 [16735702.001]
  • [Cites] Blood. 2006 May 1;107(9):3481-5 [16455952.001]
  • [Cites] Science. 2006 Mar 31;311(5769):1887-93 [16543417.001]
  • [Cites] Science. 2006 Mar 17;311(5767):1621-3 [16484451.001]
  • [Cites] Ann Hematol. 2006 Mar;85(3):139-63 [16391911.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):591-9 [16428505.001]
  • [Cites] J Lipid Res. 2006 Jan;47(1):15-31 [16278491.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3532-7 [16051737.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):6057-64 [16115951.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1355-61 [15860663.001]
  • [Cites] Mol Pharmacol. 2005 Aug;68(2):477-86 [15901852.001]
  • [Cites] Mol Pharmacol. 2005 Jun;67(6):1991-8 [15738311.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1969-78 [15632409.001]
  • [Cites] Ann Hematol. 2005 Apr;84(4):227-31 [15517268.001]
  • [Cites] Eur J Haematol. 2004 Dec;73(6):418-26 [15522064.001]
  • [Cites] J Biol Chem. 1999 Sep 17;274(38):27010-7 [10480914.001]
  • [Cites] Blood. 1999 Aug 1;94(3):1086-99 [10419902.001]
  • [Cites] Leukemia. 1999 Jun;13(6):843-9 [10360370.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):872-81 [9508168.001]
  • [Cites] Leukemia. 1997 Aug;11(8):1193-6 [9264368.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2626-32 [8653708.001]
  • [Cites] J Biol Chem. 1995 Apr 21;270(16):9031-4 [7721814.001]
  • [Cites] Oncogene. 1994 Feb;9(2):621-8 [8290273.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 May 1;88(9):3812-6 [2023931.001]
  • [Cites] Blood. 1992 Apr 15;79(8):1924-30 [1562720.001]
  • [Cites] Blood. 1990 Jan 1;75(1):27-32 [2403818.001]
  • [Cites] Lancet. 1982 Dec 11;2(8311):1345-6 [6128632.001]
  • [Cites] Blood. 2004 Oct 1;104(7):1940-51 [15217827.001]
  • [Cites] BMC Cancer. 2004 Aug 25;4:56 [15329151.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1605-16 [15084693.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2001;41:53-77 [11264450.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1655-69 [10961860.001]
  • [Cites] Invest New Drugs. 1999;17(3):241-58 [10665477.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Mol Cell Biol. 2000 Jan;20(1):139-48 [10594016.001]
  • [Cites] Oncogene. 1999 Dec 9;18(52):7514-26 [10602510.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2589-96 [18160667.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1692-7 [12411300.001]
  • [Cites] Leuk Res. 2003 Apr;27(4):313-21 [12531222.001]
  • [Cites] Clin Cancer Res. 2002 Jun;8(6):2002-9 [12060646.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Jun;3(6):430-40 [12042765.001]
  • [Cites] Blood. 2001 Sep 1;98(5):1312-20 [11520776.001]
  • [Cites] Cancer Invest. 2007 Sep;25(6):484-94 [17882662.001]
  • [Cites] Blood. 2007 Sep 15;110(6):2102-9 [17536018.001]
  • [Cites] Leukemia. 2007 Sep;21(9):1964-70 [17581608.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5151-6 [17351110.001]
  • [Cites] J Clin Oncol. 2007 May 10;25(14):1908-15 [17488990.001]
  • [Cites] Blood. 2007 May 15;109(10):4158-63 [17264294.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1287-92 [15051776.001]
  • [Cites] Mol Cancer Ther. 2004 Feb;3(2):179-86 [14985458.001]
  • [Cites] Semin Oncol. 2004 Feb;31(1 Suppl 1):28-39 [14981578.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4527-34 [12947010.001]
  • [Cites] Trends Biochem Sci. 2003 Nov;28(11):573-6 [14607085.001]
  • (PMID = 19707379.001).
  • [ISSN] 1177-5475
  • [Journal-full-title] Biologics : targets & therapy
  • [ISO-abbreviation] Biologics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2721391
  • [Keywords] NOTNLM ; acute myelogenous leukemia (AML) / farnesylation / farnesyltransferase inhibitor / gene expression / signal transduction / tipifarnib
  •  go-up   go-down


80. Nishikawa R: [Treatment of glioma with temozolomide]. Brain Nerve; 2009 Jul;61(7):849-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Currently, chemotherapy with TMZ is an interesting alternative to radiotherapy in patients with very large tumors or in the elderly who are exposed to a higher risk of delayed neurotoxicity.
  • Treatment-induced myelodysplastic syndrome with or without acute myeloblastic leukemia is a well-recognized late treatment-related complication associated with TMZ administration.
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carmustine / administration & dosage. DNA Damage. Humans. Leukemia, Myeloid, Acute / chemically induced. Lomustine / administration & dosage. Myelodysplastic Syndromes / chemically induced. Neoplasms, Second Primary / chemically induced. O(6)-Methylguanine-DNA Methyltransferase / metabolism. O(6)-Methylguanine-DNA Methyltransferase / physiology

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19618863.001).
  • [ISSN] 1881-6096
  • [Journal-full-title] Brain and nerve = Shinkei kenkyū no shinpo
  • [ISO-abbreviation] Brain Nerve
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7BRF0Z81KG / Lomustine; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; U68WG3173Y / Carmustine
  • [Number-of-references] 21
  •  go-up   go-down


81. Lee EH, Tahk SJ, Shin JH, Lee YW, Song R: [Development and a psychometric evaluation of cardiovascular disease-specific quality of life scale for Koreans]. Taehan Kanho Hakhoe Chi; 2007 Apr;37(3):313-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Development and a psychometric evaluation of cardiovascular disease-specific quality of life scale for Koreans].
  • PURPOSE: Health-related quality of life (HRQOL) in patients with cardiovascular disease in Korea has rarely been studied, mostly due to the lack of a psychometrically validated disease-specific instrument.
  • One item was deleted based upon the MDS.
  • CONCLUSION: The CD-QOL is a easily applicable instrument with excellent psychometric properties of content, criterion, factorial, convergent, and known-groups validity, and internal consistency reliability in Korean patients with cardiovascular disease.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17615452.001).
  • [ISSN] 1598-2874
  • [Journal-full-title] Taehan Kanho Hakhoe chi
  • [ISO-abbreviation] Taehan Kanho Hakhoe Chi
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] Korea (South)
  •  go-up   go-down


82. Huls G, Mulder AB, Rosati S, van de Loosdrecht AA, Vellenga E, de Wolf JT: Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis. Blood; 2010 Jul 15;116(2):180-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As lenalidomide has shown to be efficacious in both myelodysplastic syndromes and myeloproliferative neoplasms, we have treated 2 RARS-T patients, who were transfusion dependent, with lenalidomide.
  • We report the results of lenalidomide treatment in these patients and show that lenalidomide has clinical activity in this rare disorder.

  • Genetic Alliance. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • Hazardous Substances Data Bank. PYRIDOXINE HYDROCHLORIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20194893.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anabolic Agents; 0 / Antineoplastic Agents; 11096-26-7 / Erythropoietin; 12001-76-2 / Vitamin B Complex; 4Z8R6ORS6L / Thalidomide; EC 2.7.10.2 / Janus Kinase 2; F0P408N6V4 / lenalidomide; KV2JZ1BI6Z / Pyridoxine
  •  go-up   go-down


83. Steensma DP, Neiger JD, Porcher JC, Keats JJ, Bergsagel PL, Dennis TR, Knudson RA, Jenkins RB, Santana-Davila R, Kumar R, Ketterling RP: Rearrangements and amplification of IER3 (IEX-1) represent a novel and recurrent molecular abnormality in myelodysplastic syndromes. Cancer Res; 2009 Oct 1;69(19):7518-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rearrangements and amplification of IER3 (IEX-1) represent a novel and recurrent molecular abnormality in myelodysplastic syndromes.
  • Here, we describe breakpoint cloning of a t(6;9)(p21;q34) translocation from a patient with a myelodysplastic syndrome (MDS), facilitated by conversion technology and array-based comparative genomic hybridization, which revealed a rearrangement translocating the IER3 coding region away from critical flanking/regulatory elements and to a transcript-poor chromosomal region, markedly decreasing expression.
  • Using split-signal and locus-specific fluorescence in situ hybridization (FISH) probes, we analyzed 204 patients with diverse hematological malignancies accompanied by clonal chromosome 6p21 abnormalities, and found 8 additional patients with MDS with IER3 rearrangements (translocations or amplification).
  • Although FISH studies on 157 additional samples from patients with MDS and a normal-karyotype were unrevealing, and sequencing the IER3 coding and proximal promoter regions of 74 MDS patients disclosed no point mutations, reverse transcription-PCR results suggested that dysregulated expression of IER3 is common in MDS (61% >4-fold increase or decrease in expression with decreased expression primarily in early MDS and increased expression primarily in later MDS progressing toward leukemia), consistent with findings in previous microarray experiments.
  • These data support involvement of IER3 in the pathobiology of MDS.

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histochem Cell Biol. 2001 Jun;115(6):489-97 [11455449.001]
  • [Cites] J Biol Chem. 2002 Apr 26;277(17):14612-21 [11844788.001]
  • [Cites] Oncogene. 2002 Oct 3;21(44):6819-28 [12360408.001]
  • [Cites] Blood. 2002 Nov 15;100(10):3553-60 [12411319.001]
  • [Cites] Apoptosis. 2003 Jan;8(1):11-8 [12510147.001]
  • [Cites] Recent Results Cancer Res. 2003;164:123-34 [12899517.001]
  • [Cites] Oncogene. 2003 Oct 9;22(44):6845-51 [14534530.001]
  • [Cites] J Steroid Biochem Mol Biol. 2004 Mar;88(3):247-59 [15120418.001]
  • [Cites] Cancer Res. 1996 Apr 1;56(7):1498-502 [8603392.001]
  • [Cites] Blood. 1997 Mar 15;89(6):2079-88 [9058730.001]
  • [Cites] Science. 1998 Aug 14;281(5379):998-1001 [9703517.001]
  • [Cites] Mol Cancer. 2005 Feb 3;4(1):9 [15691381.001]
  • [Cites] J Appl Physiol (1985). 2006 Feb;100(2):707-16 [16166241.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3106-13 [16368886.001]
  • [Cites] J Biol Chem. 2006 Jun 2;281(22):15304-11 [16567805.001]
  • [Cites] Oncogene. 2008 Feb 14;27(8):1122-34 [17704804.001]
  • [Cites] Ann Surg Oncol. 2008 Feb;15(2):609-17 [18026799.001]
  • [Cites] Curr Protoc Hum Genet. 2007 Oct;Chapter 3:Unit 3.6 [18428411.001]
  • [Cites] Int J Hematol. 2009 Mar;89(2):173-87 [19152102.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):878-83 [11782530.001]
  • (PMID = 19773435.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA100707-09; United States / NIDDK NIH HHS / DK / R21 DK077669; United States / NCI NIH HHS / CA / K12 CA90628; United States / NCI NIH HHS / CA / K12 CA090628-07; United States / NCI NIH HHS / CA / K12 CA090628; United States / NCI NIH HHS / CA / 2 P50 CA100707-067285; United States / NIDDK NIH HHS / DK / R01 DK076829; United States / NCI NIH HHS / CA / P50 CA100707; United States / NCI NIH HHS / CA / CA090628-07
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / IER3 protein, human; 0 / Membrane Proteins
  • [Other-IDs] NLM/ NIHMS140265; NLM/ PMC3157243
  •  go-up   go-down


84. Nasrollahi AR, Miladipour A, Ghanei E, Yavari P, Haghverdi F: Montelukast for treatment of refractory pruritus in patients on hemodialysis. Iran J Kidney Dis; 2007 Oct;1(2):73-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: One of the most common complaints in patients with end-stage renal disease (ESRD) is uremic pruritus.
  • RESULTS: Of 16 patients whom were included in the study, 1 died during the placebo period of myocardial infarction and another patient who received montelukast for 20 days faced hemoglobin decrease during the placebo period diagnosed as myelodysplastic syndrome.
  • CONCLUSIONS: Montelukast is more effective than placebo in the treatment of uremic pruritus not responding to the currently available antipruritus drugs, and it can be considered as a new and rather safe and effective treatment option in uremic patients.

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Itching.
  • Hazardous Substances Data Bank. MONTELUKAST .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19363280.001).
  • [ISSN] 1735-8582
  • [Journal-full-title] Iranian journal of kidney diseases
  • [ISO-abbreviation] Iran J Kidney Dis
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Iran
  • [Chemical-registry-number] 0 / Acetates; 0 / Leukotriene Antagonists; 0 / Quinolines; MHM278SD3E / montelukast
  •  go-up   go-down


85. Machefer G, Groussard C, Zouhal H, Vincent S, Youssef H, Faure H, Malardé L, Gratas-Delamarche A: Nutritional and plasmatic antioxidant vitamins status of ultra endurance athletes. J Am Coll Nutr; 2007 Aug;26(4):311-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The "Marathon des Sables" (MDS) is a competition known to induce oxidative stress.

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • Hazardous Substances Data Bank. VITAMIN E .
  • Hazardous Substances Data Bank. VITAMIN A .
  • Hazardous Substances Data Bank. BETA-CAROTENE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17906181.001).
  • [ISSN] 0731-5724
  • [Journal-full-title] Journal of the American College of Nutrition
  • [ISO-abbreviation] J Am Coll Nutr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Vitamins; 01YAE03M7J / beta Carotene; 11103-57-4 / Vitamin A; H4N855PNZ1 / alpha-Tocopherol; PQ6CK8PD0R / Ascorbic Acid
  •  go-up   go-down


86. Yoshioka T, Bensmaïa SJ, Craig JC, Hsiao SS: Texture perception through direct and indirect touch: an analysis of perceptual space for tactile textures in two modes of exploration. Somatosens Mot Res; 2007 Mar-Jun;24(1-2):53-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is not clear, however, how texture perception with a probe compares with texture perception with the bare finger.
  • From the dissimilarity judgment experiment, we found that the texture percept is similar though not identical in the two scanning modes.
  • These differences between the two modes of scanning are apparent in perceptual space for tactile textures based on multidimensional scaling (MDS) analysis.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosci. 1995 Apr;15(4):2808-18 [7722630.001]
  • [Cites] J Neurophysiol. 1995 Jan;73(1):88-101 [7714593.001]
  • [Cites] J Neurophysiol. 1996 May;75(5):1957-62 [8734594.001]
  • [Cites] J Neurophysiol. 1996 Aug;76(2):1145-65 [8871227.001]
  • [Cites] J Neurosci. 1997 Oct 1;17(19):7480-9 [9295394.001]
  • [Cites] J Neurophysiol. 1998 Nov;80(5):2446-66 [9819255.001]
  • [Cites] Annu Rev Psychol. 1999;50:305-31 [10074681.001]
  • [Cites] J Neurophysiol. 1999 Apr;81(4):1548-58 [10200190.001]
  • [Cites] Pflugers Arch. 1959;268(6):582-96 [13645220.001]
  • [Cites] Perception. 2004;33(8):1001-19 [15521697.001]
  • [Cites] J Exp Psychol. 1965 Jul;70:18-26 [14315125.001]
  • [Cites] Somatosens Mot Res. 2005 Mar-Jun;22(1-2):69-84 [16191760.001]
  • [Cites] Percept Psychophys. 2005 Jul;67(5):842-54 [16334056.001]
  • [Cites] Somatosens Mot Res. 2005 Sep;22(3):127-40 [16338822.001]
  • [Cites] Somatosens Mot Res. 2005 Sep;22(3):193-206 [16338827.001]
  • [Cites] J Neurophysiol. 2006 Mar;95(3):1771-82 [16236779.001]
  • [Cites] Somatosens Mot Res. 2005 Dec;22(4):281-97 [16503581.001]
  • [Cites] Exp Brain Res. 2000 Jun;132(3):351-61 [10883383.001]
  • [Cites] J Neurophysiol. 2000 Apr;83(4):1777-86 [10758090.001]
  • [Cites] J Neurosci. 2006 May 17;26(20):5582-8 [16707809.001]
  • [Cites] Percept Psychophys. 2000 May;62(4):695-705 [10883578.001]
  • [Cites] Percept Psychophys. 2000 Nov;62(8):1534-44 [11140177.001]
  • [Cites] J Neurosci. 2001 Sep 1;21(17):6905-16 [11517278.001]
  • [Cites] J Neurosci. 2001 Oct 15;21(20):8222-37 [11588194.001]
  • [Cites] Somatosens Mot Res. 2001;18(4):253-62 [11794728.001]
  • [Cites] Percept Psychophys. 2003 May;65(4):613-31 [12812283.001]
  • [Cites] Acta Psychol (Amst). 2003 Oct;114(2):165-84 [14529823.001]
  • [Cites] J Physiol. 1975 Feb;245(1):63-80 [1127614.001]
  • [Cites] J Neurophysiol. 1981 Dec;46(6):1192-203 [6275041.001]
  • [Cites] Exp Brain Res. 1983;49(2):291-9 [6832261.001]
  • [Cites] J Physiol. 1983 May;338:551-65 [6875970.001]
  • [Cites] J Neurosci. 1987 Jul;7(7):2168-80 [3612236.001]
  • [Cites] J Neurosci. 1987 Jul;7(7):2181-91 [3612237.001]
  • [Cites] J Neurosci. 1989 Apr;9(4):1273-9 [2703877.001]
  • [Cites] J Neurophysiol. 1989 Dec;62(6):1410-36 [2600632.001]
  • [Cites] J Neurophysiol. 1989 Dec;62(6):1437-60 [2600633.001]
  • [Cites] J Neurosci. 1990 Dec;10(12):3823-36 [2269886.001]
  • [Cites] Annu Rev Neurosci. 1992;15:227-50 [1575442.001]
  • [Cites] J Neurosci. 1992 Sep;12(9):3414-26 [1527586.001]
  • [Cites] Percept Psychophys. 1993 Dec;54(6):697-705 [8134240.001]
  • [Cites] J Neurosci. 1995 Jan;15(1 Pt 2):798-810 [7823181.001]
  • [Cites] J Physiol. 1995 Aug 15;487 ( Pt 1):243-51 [7473253.001]
  • (PMID = 17558923.001).
  • [ISSN] 0899-0220
  • [Journal-full-title] Somatosensory & motor research
  • [ISO-abbreviation] Somatosens Mot Res
  • [Language] ENG
  • [Grant] United States / NIDCD NIH HHS / DC / DC 00095; United States / NINDS NIH HHS / NS / NS054180; United States / NINDS NIH HHS / NS / NS018787-24; United States / NINDS NIH HHS / NS / P01 NS038034; United States / NINDS NIH HHS / NS / NS054180-01A1; United States / NIDCD NIH HHS / DC / R01 DC000095; United States / NINDS NIH HHS / NS / R01 NS018787-24; United States / NINDS NIH HHS / NS / R01 NS018787; United States / NINDS NIH HHS / NS / R01 NS054180; United States / NINDS NIH HHS / NS / NS38034; United States / NINDS NIH HHS / NS / R01 NS054180-01A1; United States / NINDS NIH HHS / NS / R01 NS034086; United States / NINDS NIH HHS / NS / NS34086; United States / NINDS NIH HHS / NS / NS18787
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS24802; NLM/ PMC2635116
  •  go-up   go-down


87. Boemers TM, Schimke CM: Colpo-wrap: a new continence procedure. BJU Int; 2005 May;95(7):1063-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The underlying conditions and causes for urinary incontinence was neurogenic bladder-sphincter dysfunction caused by myelodysplasia in three girls and anorectal malformation combined with a tethered spinal cord in one.

  • MedlinePlus Health Information. consumer health - Urinary Incontinence.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15839933.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


88. Lee SH, Ho SJ, Thomas DT, Giri P, Lee H, Sia H, To LB, Sullivan TR: A partial nucleated differential cell count of the bone marrow aspirate that is independent of peripheral blood dilution. Int J Lab Hematol; 2008 Dec;30(6):473-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A partial nucleated differential cell count of the bone marrow aspirate that is independent of peripheral blood dilution.
  • We show that the myeloid : erythroid (M : E) ratio of the PNDC remains approximately constant in progressively dilute aliquots of BM aspirates.
  • We determined the PNDC in 22 healthy subjects and investigated the effect of peripheral blood dilution on disease stratification of 66 BM aspirates with myelodysplastic syndromes (MDS).
  • Reclassification of MDS samples with the PNDC resulted in a change in disease category in 33.3% of 51 MDS samples with NDC myeloblast counts ranging from 3 to 26%.
  • The PNDC is independent of PBNC dilution and can be determined in dilute BM samples.
  • It alters the disease category in a significant proportion of BM aspirates with MDS and has the potential to better stratify MDS to improve clinical outcomes and treatment.
  • [MeSH-major] Blood Cell Count / methods. Bone Marrow Cells / pathology. Myelodysplastic Syndromes / blood. Myelodysplastic Syndromes / pathology


89. Wang SA, Jabbar K, Lu G, Chen SS, Galili N, Vega F, Jones D, Raza A, Kantarjian H, Garcia-Manero G, McDonnell TJ, Medeiros LJ: Trisomy 11 in myelodysplastic syndromes defines a unique group of disease with aggressive clinicopathologic features. Leukemia; 2010 Apr;24(4):740-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trisomy 11 in myelodysplastic syndromes defines a unique group of disease with aggressive clinicopathologic features.
  • Trisomy 11 in myelodysplastic syndromes (MDS) is rare, with undefined clinical significance and is currently assigned to the International Prognostic Scoring System (IPSS) intermediate-risk group.
  • Over a 15-year period, we identified 17 MDS patients with trisomy 11 either as a sole abnormality (n=10) or associated with one or two additional alterations (n=7), comprising 0.3% of all MDS cases reviewed.
  • Of 16 patients with Bone Marrow material available for review, 14 (88%) patients presented with excess blasts, 69% patients evolved to acute myeloid leukemia (AML) in a 5-month median interval and the median survival was 14 months.
  • For comparison, we studied 19 AML patients with trisomy 11 in a noncomplex karyotype, of which, a substantial subset of patients had morphologic dysplasia, and/or preexisting cytopenia(s)/MDS.
  • Genomic DNA PCR showed MLL partial tandem duplication in 5 of 10 MDS and 7 of 11 AML patients.
  • A review of literature identified 17 additional cases of MDS with trisomy 11, showing similar clinicopathologic features to our patients.
  • Compared with our historical data comprising 1165 MDS patients, MDS patients with trisomy 11 had a significantly inferior survival to patients in the IPSS intermediate-risk cytogenetic group (P=0.0002), but comparable to the poor-risk group (P=0.97).
  • We conclude that trisomy 11 in MDS correlates with clinical aggressiveness, may suggest an early/evolving AML with myelodysplasia-related changes and is best considered a high-risk cytogenetic abnormality in MDS prognostication.
  • [MeSH-major] Chromosome Disorders / genetics. Chromosomes, Human, Pair 11 / genetics. Leukemia, Myeloid, Acute / genetics. Myelodysplastic Syndromes / genetics. Myelodysplastic Syndromes / pathology. Trisomy / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Southern. DNA, Neoplasm / genetics. Female. Gene Duplication. Genes, ras / genetics. Histone-Lysine N-Methyltransferase. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Male. Middle Aged. Mutation / genetics. Myeloid-Lymphoid Leukemia Protein / genetics. Prognosis. Proto-Oncogene Proteins / genetics. Retrospective Studies. Survival Rate. fms-Like Tyrosine Kinase 3 / genetics. ras Proteins / genetics


90. Pawelec K, Matysiak M, Niewiadomska E, Rokicka-Milewska R, Kowalczyk J, Stefaniak J, Balwierz W, Załecka-Czepko E, Chybicka A, Szmyd K, Sońta-Jakimczyk D, Bubała H, Krauze A, Wysocki M, Kurylak A, Wachowiak J, Kaczmarek-Kanold M, Stolarska M, Karolczyk I, Krawczuk-Rybak M, Leszczyńska E, Urasiński T, Peregud-Pogorzelski J, Balcerska A, Włazłowski M: [Results of immunosuppressive therapy in children with severe aplastic anaemia. Report by the Polish Paediatric Leukaemia and Lymphoma Study Group]. Med Wieku Rozwoj; 2006 Jul-Sep;10(3 Pt 1):832-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of immunosuppressive therapy in children with severe aplastic anaemia. Report by the Polish Paediatric Leukaemia and Lymphoma Study Group].
  • MATERIAL AND METHODS: SAA was diagnosed in 85 children (31 girls, 54 boys) aged 2-17.5 years in the eleven centres of the Polish Paediatric Leukaemia and Lymphoma Study Group (PPLLSG) in Poland between 1993-2003 years.
  • Transformation to leukaemia or myelodysplastic syndrome (MDS) was not observed in any of our patients.

  • MedlinePlus Health Information. consumer health - Aplastic Anemia.
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317914.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antilymphocyte Serum; 0 / Immunosuppressive Agents; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


91. Mozaffarian D, Marfisi R, Levantesi G, Silletta MG, Tavazzi L, Tognoni G, Valagussa F, Marchioli R: Incidence of new-onset diabetes and impaired fasting glucose in patients with recent myocardial infarction and the effect of clinical and lifestyle risk factors. Lancet; 2007 Aug 25;370(9588):667-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of new-onset diabetes and impaired fasting glucose in patients with recent myocardial infarction and the effect of clinical and lifestyle risk factors.
  • BACKGROUND: Individuals with diabetes are at higher risk of myocardial infarction than non-diabetics.
  • However, much less is known about the incidence of, and risk factors for, development of diabetes and impaired fasting glucose in patients who have had a myocardial infarction.
  • METHODS: We used prospectively obtained data for 8291 Italian patients with a myocardial infarction within the previous 3 months, who were free of diabetes (determined by medication use, a physician-reported diagnosis, or fasting glucose > or =7 mmol/L) at baseline.
  • Associations of demographic, clinical, and lifestyle risk-factors with incidence of diabetes and impaired fasting glucose were assessed with multivariable Cox proportional hazards.
  • FINDINGS: During 26 795 person-years (mean follow-up 3.2 years [SD 0.9]), 998 individuals (12%) developed new-onset diabetes (incidence 37 cases per 1000 person-years).
  • INTERPRETATION: Compared with population-based cohorts, patients with a recent myocardial infarction had a higher annual incidence rate of impaired fasting glucose (1.8 vs 27.5% in our study) and diabetes (0.8-1.6% compared with 3.7%) in this study.
  • Thus, our results indicate that myocardial infarction could be a prediabetes risk equivalent.
  • Smoking cessation, prevention of weight gain, and consumption of typical Mediterranean foods might lower this risk, which emphasises the need for guidance on diet and other lifestyle factors for patients who have had a myocardial infarction.
  • [MeSH-major] Diabetes Mellitus, Type 2 / epidemiology. Glucose Intolerance / epidemiology. Myocardial Infarction / complications

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes Type 2.
  • MedlinePlus Health Information. consumer health - Heart Attack.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet. 2007 Aug 25;370(9588):634-5 [17719997.001]
  • (PMID = 17720018.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / K08-HL-075628
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  •  go-up   go-down


92. Garcia-Manero G: Modifying the epigenome as a therapeutic strategy in myelodysplasia. Hematology Am Soc Hematol Educ Program; 2007;:405-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modifying the epigenome as a therapeutic strategy in myelodysplasia.
  • The term epigenetics refers to a number of biochemical modifications of chromatin that, without altering the primary sequence of DNA, have a role in genomic regulation and in particular gene expression control.
  • The study of these modifications is a very active area of research both at the basic and clinical levels.
  • Clinical interest in these epigenetic alterations stems mainly from two observations.
  • This review focuses on the current clinical information regarding different forms of epigenetic therapy in patients with myelodysplastic syndromes (MDS).
  • Basic aspects of DNA methylation or histone code alterations are not covered in detail in this review.

  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18024658.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA100067; United States / NCI NIH HHS / CA / CA105771
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 43
  •  go-up   go-down


93. Akiyama N, Miyazawa K, Kanda Y, Tohyama K, Omine M, Mitani K, Ohyashiki K: Multicenter phase II trial of vitamin K(2) monotherapy and vitamin K(2) plus 1alpha-hydroxyvitamin D(3) combination therapy for low-risk myelodysplastic syndromes. Leuk Res; 2010 Sep;34(9):1151-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicenter phase II trial of vitamin K(2) monotherapy and vitamin K(2) plus 1alpha-hydroxyvitamin D(3) combination therapy for low-risk myelodysplastic syndromes.
  • We performed an open-labeled single-arm prospective phase II clinical trial of vitamin K(2) (menatetrenone: VK2) monotherapy and VK2 plus 1alpha-hydroxyvitamin D(3) (alfacalcidol: VD3) combination therapy for myelodysplastic syndromes (MDS) with refractory anemia and refractory cytopenia with multilineage dysplasia, having either low or intermediate-1 risks of the IPSS.
  • Our study demonstrated that VK2 plus VD3 combination therapy appears to be promising for improvement of anemia and thrombocytopenia with low/intermediate-1 MDS.
  • [MeSH-major] Hydroxycholecalciferols / therapeutic use. Myelodysplastic Syndromes / drug therapy. Vitamin K 2 / therapeutic use


94. Corey SJ: New agents in the treatment of childhood leukemias and myelodysplastic syndromes. Curr Oncol Rep; 2005 Nov;7(6):399-405
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New agents in the treatment of childhood leukemias and myelodysplastic syndromes.
  • Relapsed or refractory leukemia remains the most common therapeutic problem in pediatric oncology.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Enzyme Inhibitors / therapeutic use. Leukemia / drug therapy. Myelodysplastic Syndromes / drug therapy


95. Alexandrakis MG, Passam FH, Pappa CA, Sfiridaki K, Tsirakis G, Damilakis J, Stathopoulos EN, Kyriakou DS: Relation between bone marrow angiogenesis and serum levels of angiogenin in patients with myelodysplastic syndromes. Leuk Res; 2005 Jan;29(1):41-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relation between bone marrow angiogenesis and serum levels of angiogenin in patients with myelodysplastic syndromes.
  • Angiogenesis is implicated in the progression of myelodysplastic syndromes (MDS).
  • Bone marrow microvascular density (MVD), serum angiogenin (ANG) and interleukin 6 (IL-6) were measured in 67 patients with untreated MDS.
  • In the MDS group, a positive correlation was found between ANG and IL-6 (P < 0.001) and also between MVD and IL-6 (P < 0.05).
  • Using multivariate analysis, only IL-6 displayed independent prognostic value and was inversely related to MDS survival.
  • [MeSH-major] Bone Marrow / blood supply. Interleukin-6 / blood. Myelodysplastic Syndromes / blood. Neovascularization, Pathologic. Ribonuclease, Pancreatic / blood
  • [MeSH-minor] Aged. Disease Progression. Female. Humans. Male. Middle Aged. Prognosis. Risk. Survival Analysis


96. Badawi MA, Vickars LM, Chase JM, Leitch HA: Red blood cell transfusion independence following the initiation of iron chelation therapy in myelodysplastic syndrome. Adv Hematol; 2010;2010:164045
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Red blood cell transfusion independence following the initiation of iron chelation therapy in myelodysplastic syndrome.
  • A 76-year-old man with MDS type refractory cytopenia with multilineage dysplasia, intermediate-1 IPSS risk, was referred when he became transfusion dependent.
  • Over the same time course, ferritin levels decreased but did not normalize.
  • There have been eighteen other MDS patients reported showing improvement in hemoglobin level with iron chelation; nine became transfusion independent, nine had decreased transfusion requirements, and some showed improved trilineage myelopoiesis.
  • The clinical features of these patients are summarized and possible mechanisms for such an effect of iron chelation on cytopenias are discussed.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Korean Med Sci. 2008 Apr;23(2):320-3 [18437019.001]
  • [Cites] Acta Haematol. 2008;120(2):70-4 [18827475.001]
  • [Cites] Br J Haematol. 1990 Sep;76(1):148-9 [2223635.001]
  • [Cites] Br J Haematol. 1982 Jun;51(2):189-99 [6952920.001]
  • [Cites] N Engl J Med. 1994 Sep 1;331(9):567-73 [8047080.001]
  • [Cites] N Engl J Med. 1994 Sep 1;331(9):574-8 [8047081.001]
  • [Cites] Am J Hematol. 1996 Mar;51(3):243-4 [8619408.001]
  • [Cites] Br J Haematol. 1996 Aug;94(2):288-99 [8759889.001]
  • [Cites] Blood. 1997 Feb 1;89(3):739-61 [9028304.001]
  • [Cites] Blood. 1997 Mar 15;89(6):2079-88 [9058730.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1229-36 [10666195.001]
  • [Cites] J Appl Physiol (1985). 2000 Aug;89(2):680-6 [10926654.001]
  • [Cites] Blood. 2001 Aug 15;98(4):958-65 [11493439.001]
  • [Cites] Br J Haematol. 2001 Nov;115(2):239-52 [11703317.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2429-40 [12011120.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2292-302 [12239137.001]
  • [Cites] Int J Hematol. 2002 Oct;76(3):219-28 [12416732.001]
  • [Cites] Br J Haematol. 2003 Mar;120(6):1037-46 [12648074.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2670-7 [12805056.001]
  • [Cites] Cytometry A. 2004 Jul;60(1):73-80 [15229859.001]
  • [Cites] Br J Haematol. 2004 Nov;127(3):348-55 [15491298.001]
  • [Cites] Thromb Haemost. 2004 Nov;92(5):1052-9 [15543333.001]
  • [Cites] N Engl J Med. 2005 Feb 10;352(6):549-57 [15703420.001]
  • [Cites] Blood. 2005 Aug 1;106(3):841-51 [15827127.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7594-603 [16186598.001]
  • [Cites] Cancer. 2006 Apr 15;106(8):1794-803 [16532500.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:205-10 [17124062.001]
  • [Cites] Eur J Haematol. 2007 Jun;78(6):540-2 [17391307.001]
  • [Cites] Int J Biochem Cell Biol. 2008;40(3):350-4 [17451993.001]
  • [Cites] J Clin Oncol. 2007 Aug 10;25(23):3503-10 [17687155.001]
  • [Cites] Am J Hematol. 2007 Dec;82(12 Suppl):1128-31 [17963252.001]
  • [Cites] Exp Hematol. 2008 Jul;36(7):773-85 [18456387.001]
  • [Cites] Int J Hematol. 2008 Jul;88(1):24-9 [18581200.001]
  • [Cites] Am J Hematol. 2008 Nov;83(11):858-61 [18767130.001]
  • [Cites] Br J Haematol. 1992 Jan;80(1):121-4 [1536800.001]
  • (PMID = 20368773.001).
  • [ISSN] 1687-9112
  • [Journal-full-title] Advances in hematology
  • [ISO-abbreviation] Adv Hematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2846339
  •  go-up   go-down


97. Kume H, Yamazaki T, Abe M, Tanuma H, Okudaira M, Okayasu I: [Epidemiology of visceral mycoses in patients with leukemia and MDS - Analysis of the data in annual of pathological autopsy cases in Japan in 1989, 1993, 1997 and 2001]. Nihon Ishinkin Gakkai Zasshi; 2006;47(1):15-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidemiology of visceral mycoses in patients with leukemia and MDS - Analysis of the data in annual of pathological autopsy cases in Japan in 1989, 1993, 1997 and 2001].
  • To study the changes of visceral mycoses in autopsy cases, data on visceral mycosis cases with leukemia and myelodysplastic syndrome (MDS) reported in the Annual of the Pathological Autopsy Cases in Japan in 1989, 1993, 1997 and 2001 were analyzed.
  • The frequency rate of visceral mycoses with leukemia and MDS was 27.9% (435/1,557) in 1989, 23.0% (319/1,388) in 1993, 22.3% (246/1,105) in 1997 and 25.1% (260/ 1,037) in 2001, which was clearly higher than the rate of cases without leukemia and MDS: 3.4%, 2.7%, 3.5% and 3.7%, respectively.
  • Among a total of 1,260 cases with mycotic infections in the four years studied, acute lymphatic leukemia and acute myeloid leukemia were the major diseases (35.5% and 33.5%, respectively) followed by MDS (29.0%).
  • [MeSH-major] Leukemia / complications. Mycoses / epidemiology. Myelodysplastic Syndromes / complications


98. Wang XQ, Sino-US Leukemia Cooperative Group of Shanghai: [Prospective clinical study of diagnosis and classification for 282 cases with primary myelodysplastic syndrome]. Zhonghua Xue Ye Xue Za Zhi; 2006 Aug;27(8):546-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prospective clinical study of diagnosis and classification for 282 cases with primary myelodysplastic syndrome].
  • OBJECTIVE: To summarize the diagnostic experience of primary myelodysplastic syndromes (MDS) in order to improve the diagnostic level.
  • Diagnoses of 282 MDS cases were defined according to FAB and WHO classification.
  • RESULTS: The median age at MDS onset was 56.
  • Presence of immature granulocytes and erythroblasts in peripheral blood (PB) were found in 67% and 48% of the MDS patients, respectively.
  • The abnormality of chromosome (31.2%) was lower than that in the West, and similar to that in Japan.
  • Eighty nine percent of the MDS patients could be diagnosed on cell morphology in PB and bone marrow (BM) aspirate.
  • Ninety four percent of MDS could be diagnosed by combination of BM aspirate and core biopsy.
  • CONCLUSIONS: The subtypes and clinical features of Chinese MDS patients were somewhat different from the West, but similar to that in Japan.
  • [MeSH-major] Myelodysplastic Syndromes / classification. Myelodysplastic Syndromes / diagnosis


99. Park S, Grabar S, Kelaidi C, Beyne-Rauzy O, Picard F, Bardet V, Coiteux V, Leroux G, Lepelley P, Daniel MT, Cheze S, Mahé B, Ferrant A, Ravoet C, Escoffre-Barbe M, Adès L, Vey N, Aljassem L, Stamatoullas A, Mannone L, Dombret H, Bourgeois K, Greenberg P, Fenaux P, Dreyfus F, GFM group (Groupe Francophone des Myélodysplasies): Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood; 2008 Jan 15;111(2):574-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience.
  • We analyzed prognostic factors of response, response duration, and possible impact on survival of epoetin alpha, epoetin beta, or darbepoetin alpha (DAR) with or without granulocyte colony-stimulating factor in 403 myelodysplastic syndrome (MDS) patients.
  • Significantly higher response rates were observed with less than 10% blasts, low and int-1 International Prognostic Scoring System (IPSS), red blood cell transfusion independence, serum EPO level less than 200 IU/L, and, with IWG 2006 criteria only, shorter interval between diagnosis and treatment.
  • Significantly longer response duration was associated with major response (IWG 2000 criteria), IPSS low to INT-1, blasts less than 5%, and absence of multilineage dysplasia.
  • However, among those IWG 2000 minor responders, response duration did not differ between IWG 2006 responders and nonresponders.
  • Multivariate adjusted comparisons of survival between our cohort and the untreated MDS cohort used to design IPSS showed similar rate of progression to acute myeloid leukemia in both cohorts, but significantly better overall survival in our cohort, suggesting that epoetin or DAR treatment may have a favorable survival impact in MDS.
  • [MeSH-major] Blast Crisis / drug therapy. Blast Crisis / mortality. Erythropoietin / administration & dosage. Granulocyte Colony-Stimulating Factor / administration & dosage. Myelodysplastic Syndromes / mortality. Myelodysplastic Syndromes / therapy
  • [MeSH-minor] Aged. Cohort Studies. Disease-Free Survival. Erythrocyte Transfusion. Female. Humans. Male. Predictive Value of Tests. Survival Rate. Time Factors


100. Haugh R: Are you looking for a fresh start with your MDs? Hosp Health Netw; 2005 May;79(5):36-8, 40-2, 2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are you looking for a fresh start with your MDs?
  • This spring saw a welcome thaw in the icy relations between some hospitals and physicians, as it dawns on both sides that cooperation, not alienation, is essential for them to flourish.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hosp Health Netw. 2005 Jul;79(7):10, 12 [16128304.001]
  • (PMID = 15971796.001).
  • [ISSN] 1068-8838
  • [Journal-full-title] Hospitals & health networks
  • [ISO-abbreviation] Hosp Health Netw
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement